If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> including biology and use of blood stem cells<br /> Volume 49 Supplement 1 March 2014 www.nature.com/bmt<br /> The official journal of the European Group for Blood and Marrow Transplantation<br /> Welcome Address<br /> Dear friends,<br /> On behalf of the EBMT and of the Local Organizing Committee, it is our pleasure to invite you to the 40th<br /> Annual Meeting of the EBMT, the 30th Meeting of the EBMT Nurses Group, the 13th Meeting of the EBMT<br /> Data Management Group, the 6th Meeting of the Quality Management Group, the 8th EBMT Patient & Family<br /> and the 1st Donor Day. This anniversary will be celebrated in Milan in coincidence with the Annual EBMT<br /> Meeting. The whole organization is determined to make this historical milestone a high-profile and<br /> unforgettable event.<br /> EBMT has grown considerably in the last few years, and we h<a title="EBMT Supplement 2014 page 1" href="http://viewer.zmags.com/publication/d5f1c0b9?page=1"> </a> <a title="EBMT Supplement 2014 page 2" href="http://viewer.zmags.com/publication/d5f1c0b9?page=2"> Welcome Address Dear friends, On behalf of the</a> <a title="EBMT Supplement 2014 page 3" href="http://viewer.zmags.com/publication/d5f1c0b9?page=3"> Organising Committee Congress President Marco B</a> <a title="EBMT Supplement 2014 page 4" href="http://viewer.zmags.com/publication/d5f1c0b9?page=4"> EBMT Lectures 1998–2014 1998 Treating CML: pres</a> <a title="EBMT Supplement 2014 page 5" href="http://viewer.zmags.com/publication/d5f1c0b9?page=5"> Van Bekkum Awards 1998–2014 1998 Induction of a</a> <a title="EBMT Supplement 2014 page 6" href="http://viewer.zmags.com/publication/d5f1c0b9?page=6"> 2007 Single nucleotide polymorphisms of the NOD2/</a> <a title="EBMT Supplement 2014 page 7" href="http://viewer.zmags.com/publication/d5f1c0b9?page=7"> 2014 T Cells engineered with a chimeric antigen r</a> <a title="EBMT Supplement 2014 page 8" href="http://viewer.zmags.com/publication/d5f1c0b9?page=8"> Reviewers We would like to thank the following</a> <a title="EBMT Supplement 2014 page 9" href="http://viewer.zmags.com/publication/d5f1c0b9?page=9"> March 2014 </a> <a title="EBMT Supplement 2014 page 10" href="http://viewer.zmags.com/publication/d5f1c0b9?page=10"> Tolerance, Chimerism and Immune reconstitution Au</a> <a title="EBMT Supplement 2014 page 11" href="http://viewer.zmags.com/publication/d5f1c0b9?page=11"> PHYSICIANS ABSTRACTS Van Bekkum Award PH</a> <a title="EBMT Supplement 2014 page 12" href="http://viewer.zmags.com/publication/d5f1c0b9?page=12"> Results: Clinical characteristics of patients all</a> <a title="EBMT Supplement 2014 page 13" href="http://viewer.zmags.com/publication/d5f1c0b9?page=13"> [PH-O004] Table I Upfront MUD/MMUD HSCT (n=27) Me</a> <a title="EBMT Supplement 2014 page 14" href="http://viewer.zmags.com/publication/d5f1c0b9?page=14"> PH-O006 AUTOLOGOUS HAEMOPOETIC STEM CELL TRANSPLA</a> <a title="EBMT Supplement 2014 page 15" href="http://viewer.zmags.com/publication/d5f1c0b9?page=15"> generation, T cell proliferation was analyzed. At</a> <a title="EBMT Supplement 2014 page 16" href="http://viewer.zmags.com/publication/d5f1c0b9?page=16"> ORAL SESSIONS Acute Leukemia/MDS PH-O008</a> <a title="EBMT Supplement 2014 page 17" href="http://viewer.zmags.com/publication/d5f1c0b9?page=17"> dose reductions. Allogenic HSCT was performed in </a> <a title="EBMT Supplement 2014 page 18" href="http://viewer.zmags.com/publication/d5f1c0b9?page=18"> possibility that adult ALL shared some common fea</a> <a title="EBMT Supplement 2014 page 19" href="http://viewer.zmags.com/publication/d5f1c0b9?page=19"> PH-O014 NON-LINEAR CLONAL EVOLUTION OF LEUKEMIA D</a> <a title="EBMT Supplement 2014 page 20" href="http://viewer.zmags.com/publication/d5f1c0b9?page=20"> Leukemic blasts subjected to T cell-mediated immu</a> <a title="EBMT Supplement 2014 page 21" href="http://viewer.zmags.com/publication/d5f1c0b9?page=21"> bearing mice. Also the multilineage reconstitutio</a> <a title="EBMT Supplement 2014 page 22" href="http://viewer.zmags.com/publication/d5f1c0b9?page=22"> [PH-O019] I</a> <a title="EBMT Supplement 2014 page 23" href="http://viewer.zmags.com/publication/d5f1c0b9?page=23"> PH-O021 CYTOMEGALOVIRUS PEPTIDE VACCINATION RESUL</a> <a title="EBMT Supplement 2014 page 24" href="http://viewer.zmags.com/publication/d5f1c0b9?page=24"> Factors influencing the risk of BSI and survival </a> <a title="EBMT Supplement 2014 page 25" href="http://viewer.zmags.com/publication/d5f1c0b9?page=25"> associated with mortality (adjusted HR, 4.4; 95% </a> <a title="EBMT Supplement 2014 page 26" href="http://viewer.zmags.com/publication/d5f1c0b9?page=26"> affected non-relapse mortality both in CBT and BM</a> <a title="EBMT Supplement 2014 page 27" href="http://viewer.zmags.com/publication/d5f1c0b9?page=27"> efficacy of anticancer monoclonal antibodies (mAb</a> <a title="EBMT Supplement 2014 page 28" href="http://viewer.zmags.com/publication/d5f1c0b9?page=28"> ingly, keratinocytes expressed lower levels of IC</a> <a title="EBMT Supplement 2014 page 29" href="http://viewer.zmags.com/publication/d5f1c0b9?page=29"> expanded ex vivo following clinical-grade protoco</a> <a title="EBMT Supplement 2014 page 30" href="http://viewer.zmags.com/publication/d5f1c0b9?page=30"> addition, we identified a combination of biomarke</a> <a title="EBMT Supplement 2014 page 31" href="http://viewer.zmags.com/publication/d5f1c0b9?page=31"> for clonal deletion of self-reactive T cells. The</a> <a title="EBMT Supplement 2014 page 32" href="http://viewer.zmags.com/publication/d5f1c0b9?page=32"> cytokine expression of slanDC in colorectal biops</a> <a title="EBMT Supplement 2014 page 33" href="http://viewer.zmags.com/publication/d5f1c0b9?page=33"> Tolerance, Chimerism and Immune Reconstitution </a> <a title="EBMT Supplement 2014 page 34" href="http://viewer.zmags.com/publication/d5f1c0b9?page=34"> PH-O043 HIGH FREQUENCY OF T MEMORY STEM CELLS PRE</a> <a title="EBMT Supplement 2014 page 35" href="http://viewer.zmags.com/publication/d5f1c0b9?page=35"> PH-O045 PREDICTABLE PATTERNS OF VARIABILITY IN ST</a> <a title="EBMT Supplement 2014 page 36" href="http://viewer.zmags.com/publication/d5f1c0b9?page=36"> HLA matched SCT is more controversial. The missin</a> <a title="EBMT Supplement 2014 page 37" href="http://viewer.zmags.com/publication/d5f1c0b9?page=37"> than younger patients. This leads to an increased</a> <a title="EBMT Supplement 2014 page 38" href="http://viewer.zmags.com/publication/d5f1c0b9?page=38"> with a median dose of 6 mg/kg. Patients received </a> <a title="EBMT Supplement 2014 page 39" href="http://viewer.zmags.com/publication/d5f1c0b9?page=39"> 141 days, p<0.001). When acute leukaemia was exam</a> <a title="EBMT Supplement 2014 page 40" href="http://viewer.zmags.com/publication/d5f1c0b9?page=40"> different in the grafts obtained after HSC mobili</a> <a title="EBMT Supplement 2014 page 41" href="http://viewer.zmags.com/publication/d5f1c0b9?page=41"> PH-O057 EFFICACY OF ECULIZUMAB IN ALLOGENIC STEM </a> <a title="EBMT Supplement 2014 page 42" href="http://viewer.zmags.com/publication/d5f1c0b9?page=42"> Comparing the mean value of the FACT-G (mean=85.7</a> <a title="EBMT Supplement 2014 page 43" href="http://viewer.zmags.com/publication/d5f1c0b9?page=43"> PH-O061 HIGH IMPACT OF NEUROLOGICAL COMPLICATIONS</a> <a title="EBMT Supplement 2014 page 44" href="http://viewer.zmags.com/publication/d5f1c0b9?page=44"> 41 (63%) of the survivors (63%) had no active GvH</a> <a title="EBMT Supplement 2014 page 45" href="http://viewer.zmags.com/publication/d5f1c0b9?page=45"> [PH-O064] EBMT Score (modifiedwithout DOD) </a> <a title="EBMT Supplement 2014 page 46" href="http://viewer.zmags.com/publication/d5f1c0b9?page=46"> PH-O066 EBMT PROSPECTIVE NON-INTERVENTIONAL STUDY</a> <a title="EBMT Supplement 2014 page 47" href="http://viewer.zmags.com/publication/d5f1c0b9?page=47"> hemorrhage (n=2), or other causes (n=5). VOD was </a> <a title="EBMT Supplement 2014 page 48" href="http://viewer.zmags.com/publication/d5f1c0b9?page=48"> neutrophil and platelet engraftment were 88% (±4%</a> <a title="EBMT Supplement 2014 page 49" href="http://viewer.zmags.com/publication/d5f1c0b9?page=49"> (PGD), combined with human leukocyte antigen (HLA</a> <a title="EBMT Supplement 2014 page 50" href="http://viewer.zmags.com/publication/d5f1c0b9?page=50"> Results: The median age was50 years (18–70). 58 p</a> <a title="EBMT Supplement 2014 page 51" href="http://viewer.zmags.com/publication/d5f1c0b9?page=51"> improvement in outcome after allogeneic hematopoi</a> <a title="EBMT Supplement 2014 page 52" href="http://viewer.zmags.com/publication/d5f1c0b9?page=52"> through short-lasting ablation of the immune syst</a> <a title="EBMT Supplement 2014 page 53" href="http://viewer.zmags.com/publication/d5f1c0b9?page=53"> [PH-O079] independently p</a> <a title="EBMT Supplement 2014 page 54" href="http://viewer.zmags.com/publication/d5f1c0b9?page=54"> effector cells, followed by transplantation of he</a> <a title="EBMT Supplement 2014 page 55" href="http://viewer.zmags.com/publication/d5f1c0b9?page=55"> relapse/progression of the disease in 9%. Transpl</a> <a title="EBMT Supplement 2014 page 56" href="http://viewer.zmags.com/publication/d5f1c0b9?page=56"> [PH-O085] G-CSF (n=27) No G-</a> <a title="EBMT Supplement 2014 page 57" href="http://viewer.zmags.com/publication/d5f1c0b9?page=57"> 200 consecutive ECP apheresis procedures that had</a> <a title="EBMT Supplement 2014 page 58" href="http://viewer.zmags.com/publication/d5f1c0b9?page=58"> as well as platelet loss, collection effica</a> <a title="EBMT Supplement 2014 page 59" href="http://viewer.zmags.com/publication/d5f1c0b9?page=59"> PH-O090 COLLECTION AND TRANSPLANTATION OF AUTOLOG</a> <a title="EBMT Supplement 2014 page 60" href="http://viewer.zmags.com/publication/d5f1c0b9?page=60"> Cell and Gene Therapy 2 PH-O092 LONG-TERM IMMU</a> <a title="EBMT Supplement 2014 page 61" href="http://viewer.zmags.com/publication/d5f1c0b9?page=61"> PH-O094 TCR TRANSGENIC ALLO-RESTRICTED T CELLS DI</a> <a title="EBMT Supplement 2014 page 62" href="http://viewer.zmags.com/publication/d5f1c0b9?page=62"> directly compare the safety and efficacy profile </a> <a title="EBMT Supplement 2014 page 63" href="http://viewer.zmags.com/publication/d5f1c0b9?page=63"> Results: Monitoring of 75 transplantations, </a> <a title="EBMT Supplement 2014 page 64" href="http://viewer.zmags.com/publication/d5f1c0b9?page=64"> PH-O099 MONITORING OF MINIMAL RESIDUAL DISEASE AF</a> <a title="EBMT Supplement 2014 page 65" href="http://viewer.zmags.com/publication/d5f1c0b9?page=65"> PH-O101 OPTIMIZATION OF ECULIZUMAB THERAPY IN CHI</a> <a title="EBMT Supplement 2014 page 66" href="http://viewer.zmags.com/publication/d5f1c0b9?page=66"> [PH-O102] Outcome </a> <a title="EBMT Supplement 2014 page 67" href="http://viewer.zmags.com/publication/d5f1c0b9?page=67"> PH-O104 EFFECT OF CD8+ CELL CONTENT ON UMBILICAL </a> <a title="EBMT Supplement 2014 page 68" href="http://viewer.zmags.com/publication/d5f1c0b9?page=68"> conditioning regimen and GVHD prophylaxis), and p</a> <a title="EBMT Supplement 2014 page 69" href="http://viewer.zmags.com/publication/d5f1c0b9?page=69"> are alive. Pts receiving flu-cy-TBI (n=17) had a </a> <a title="EBMT Supplement 2014 page 70" href="http://viewer.zmags.com/publication/d5f1c0b9?page=70"> Histology reports were reviewed by an expert hema</a> <a title="EBMT Supplement 2014 page 71" href="http://viewer.zmags.com/publication/d5f1c0b9?page=71"> The objective of the current study was to investi</a> <a title="EBMT Supplement 2014 page 72" href="http://viewer.zmags.com/publication/d5f1c0b9?page=72"> PH-O113 AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSP</a> <a title="EBMT Supplement 2014 page 73" href="http://viewer.zmags.com/publication/d5f1c0b9?page=73"> Discussion: UCBT is a suitable option for infants</a> <a title="EBMT Supplement 2014 page 74" href="http://viewer.zmags.com/publication/d5f1c0b9?page=74"> [PH-O116] Discussion: Children </a> <a title="EBMT Supplement 2014 page 75" href="http://viewer.zmags.com/publication/d5f1c0b9?page=75"> Discussion: We here provide evidence that both ma</a> <a title="EBMT Supplement 2014 page 76" href="http://viewer.zmags.com/publication/d5f1c0b9?page=76"> was introduced with a modification towards a rand</a> <a title="EBMT Supplement 2014 page 77" href="http://viewer.zmags.com/publication/d5f1c0b9?page=77"> PH-O123 ADJUVANT HIGH-DOSE CHEMOTHERAPY WITH AUTO</a> <a title="EBMT Supplement 2014 page 78" href="http://viewer.zmags.com/publication/d5f1c0b9?page=78"> PH-O125 CYTOKINE-INDUCED KILLER (CIK) CELLS EFFEC</a> <a title="EBMT Supplement 2014 page 79" href="http://viewer.zmags.com/publication/d5f1c0b9?page=79"> PH-O127 ALLOGENEIC STEM CELL TRANSPLANTATION FOR </a> <a title="EBMT Supplement 2014 page 80" href="http://viewer.zmags.com/publication/d5f1c0b9?page=80"> WBC at HCT median 1.5 (0.1–14.9) % blasts (blood)</a> <a title="EBMT Supplement 2014 page 81" href="http://viewer.zmags.com/publication/d5f1c0b9?page=81"> planted in CR1 (30%), 55 pts in CR2 or higher CR </a> <a title="EBMT Supplement 2014 page 82" href="http://viewer.zmags.com/publication/d5f1c0b9?page=82"> conducted a multicenter randomized phase III tria</a> <a title="EBMT Supplement 2014 page 83" href="http://viewer.zmags.com/publication/d5f1c0b9?page=83"> PH-O134 HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STE</a> <a title="EBMT Supplement 2014 page 84" href="http://viewer.zmags.com/publication/d5f1c0b9?page=84"> the two (PBSCMix). Median stem cell dose was: PBS</a> <a title="EBMT Supplement 2014 page 85" href="http://viewer.zmags.com/publication/d5f1c0b9?page=85"> Disclosure of Interest: K. Schönberg: None Declar</a> <a title="EBMT Supplement 2014 page 86" href="http://viewer.zmags.com/publication/d5f1c0b9?page=86"> PH-O139 LACK OF DONOR DERIVED IL-17A AND IL-17F A</a> <a title="EBMT Supplement 2014 page 87" href="http://viewer.zmags.com/publication/d5f1c0b9?page=87"> In multivariate analysis, the following factors w</a> <a title="EBMT Supplement 2014 page 88" href="http://viewer.zmags.com/publication/d5f1c0b9?page=88"> [PH-O142] </a> <a title="EBMT Supplement 2014 page 89" href="http://viewer.zmags.com/publication/d5f1c0b9?page=89"> incidence of aGVHD (HR=0.31, 95%, CI=0.17–0.</a> <a title="EBMT Supplement 2014 page 90" href="http://viewer.zmags.com/publication/d5f1c0b9?page=90"> PH-O145 Fig1 Kaplan-Meie</a> <a title="EBMT Supplement 2014 page 91" href="http://viewer.zmags.com/publication/d5f1c0b9?page=91"> a Flu-ivBu2 regimen for AML in CR1 between 2003 a</a> <a title="EBMT Supplement 2014 page 92" href="http://viewer.zmags.com/publication/d5f1c0b9?page=92"> GM-CSF and G-CSF for neutropenic patients undergo</a> <a title="EBMT Supplement 2014 page 93" href="http://viewer.zmags.com/publication/d5f1c0b9?page=93"> Materials (or patients) and Methods: Allogeneic H</a> <a title="EBMT Supplement 2014 page 94" href="http://viewer.zmags.com/publication/d5f1c0b9?page=94"> providing protection from advanced bacterial and </a> <a title="EBMT Supplement 2014 page 95" href="http://viewer.zmags.com/publication/d5f1c0b9?page=95"> Late Effects 2 PH-O155 CAPILLARY LEAK SYNDROME</a> <a title="EBMT Supplement 2014 page 96" href="http://viewer.zmags.com/publication/d5f1c0b9?page=96"> are associated with a reduced risk of late relaps</a> <a title="EBMT Supplement 2014 page 97" href="http://viewer.zmags.com/publication/d5f1c0b9?page=97"> [PH-O158] PH-O15</a> <a title="EBMT Supplement 2014 page 98" href="http://viewer.zmags.com/publication/d5f1c0b9?page=98"> Health, Labour and Welfare in 2008. Membranous TM</a> <a title="EBMT Supplement 2014 page 99" href="http://viewer.zmags.com/publication/d5f1c0b9?page=99"> WORKING PARTIES Acute Leukaemia WP-O001 </a> <a title="EBMT Supplement 2014 page 100" href="http://viewer.zmags.com/publication/d5f1c0b9?page=100"> genetic diseases. Yet, the procedure is accompani</a> <a title="EBMT Supplement 2014 page 101" href="http://viewer.zmags.com/publication/d5f1c0b9?page=101"> reticulin or collagen fibrosis in the BM. Monitor</a> <a title="EBMT Supplement 2014 page 102" href="http://viewer.zmags.com/publication/d5f1c0b9?page=102"> binding of thrombopoietin to the receptor c-MPL o</a> <a title="EBMT Supplement 2014 page 103" href="http://viewer.zmags.com/publication/d5f1c0b9?page=103"> and into 6 age groups based on their age at the t</a> <a title="EBMT Supplement 2014 page 104" href="http://viewer.zmags.com/publication/d5f1c0b9?page=104"> independent reviewer according to Schanz et al. B</a> <a title="EBMT Supplement 2014 page 105" href="http://viewer.zmags.com/publication/d5f1c0b9?page=105"> better patient selection and increase of center e</a> <a title="EBMT Supplement 2014 page 106" href="http://viewer.zmags.com/publication/d5f1c0b9?page=106"> selection, treatment protocols, and data registra</a> <a title="EBMT Supplement 2014 page 107" href="http://viewer.zmags.com/publication/d5f1c0b9?page=107"> WP-O022 BRINGING MESENCHYMAL STEM CELLS INTO THE </a> <a title="EBMT Supplement 2014 page 108" href="http://viewer.zmags.com/publication/d5f1c0b9?page=108"> WP-O025 ROLE OF AUTOLOGOUS TRANSPLANTATION IN GER</a> <a title="EBMT Supplement 2014 page 109" href="http://viewer.zmags.com/publication/d5f1c0b9?page=109"> WP-O028 EBMT RETROSPECTIVE STUDIES IN GERM CELL T</a> <a title="EBMT Supplement 2014 page 110" href="http://viewer.zmags.com/publication/d5f1c0b9?page=110"> Paediatrics & Inborn Errors WP-O031 TECHNICAL </a> <a title="EBMT Supplement 2014 page 111" href="http://viewer.zmags.com/publication/d5f1c0b9?page=111"> PHYSICIANS POSTER SESSIONS Acute Leukaemia</a> <a title="EBMT Supplement 2014 page 112" href="http://viewer.zmags.com/publication/d5f1c0b9?page=112"> PH-P003 THIOTEPA-BASED CONDITIONING PRIOR TO ALLO</a> <a title="EBMT Supplement 2014 page 113" href="http://viewer.zmags.com/publication/d5f1c0b9?page=113"> 2 year outcome </a> <a title="EBMT Supplement 2014 page 114" href="http://viewer.zmags.com/publication/d5f1c0b9?page=114"> NKp46 expression at diagnosis on clinical outcome</a> <a title="EBMT Supplement 2014 page 115" href="http://viewer.zmags.com/publication/d5f1c0b9?page=115"> experience with three JMML patients show that a l</a> <a title="EBMT Supplement 2014 page 116" href="http://viewer.zmags.com/publication/d5f1c0b9?page=116"> PH-P012 THIOTEPA-BASED VS TBI-BASED MYELOABLATIVE</a> <a title="EBMT Supplement 2014 page 117" href="http://viewer.zmags.com/publication/d5f1c0b9?page=117"> may be achieved. Prospective trials are warranted</a> <a title="EBMT Supplement 2014 page 118" href="http://viewer.zmags.com/publication/d5f1c0b9?page=118"> PH-P016 IMPACT OF NPM1 MUTATION ON THE OUTCOME OF</a> <a title="EBMT Supplement 2014 page 119" href="http://viewer.zmags.com/publication/d5f1c0b9?page=119"> PH-P018 OUTCOMES OF AML PATIENTS WHO RELAPSE AFTE</a> <a title="EBMT Supplement 2014 page 120" href="http://viewer.zmags.com/publication/d5f1c0b9?page=120"> and Leipzig for refractory AML between 2006 and J</a> <a title="EBMT Supplement 2014 page 121" href="http://viewer.zmags.com/publication/d5f1c0b9?page=121"> Results: 65/69 pts (94%) received one or two cycl</a> <a title="EBMT Supplement 2014 page 122" href="http://viewer.zmags.com/publication/d5f1c0b9?page=122"> Discussion: Altogether, our findings reveal </a> <a title="EBMT Supplement 2014 page 123" href="http://viewer.zmags.com/publication/d5f1c0b9?page=123"> (haplo-HSCT) performed during the first complete </a> <a title="EBMT Supplement 2014 page 124" href="http://viewer.zmags.com/publication/d5f1c0b9?page=124"> following causes: disease relapse/progression in </a> <a title="EBMT Supplement 2014 page 125" href="http://viewer.zmags.com/publication/d5f1c0b9?page=125"> donors (MUD). Pts had mostly intermediate (51%) o</a> <a title="EBMT Supplement 2014 page 126" href="http://viewer.zmags.com/publication/d5f1c0b9?page=126"> Results: A median of 7 x106 CD34+/Kg and 2.7 x108</a> <a title="EBMT Supplement 2014 page 127" href="http://viewer.zmags.com/publication/d5f1c0b9?page=127"> PH-P034 PATIENTS WITH PRIMARY REFRACTORY OR RELAP</a> <a title="EBMT Supplement 2014 page 128" href="http://viewer.zmags.com/publication/d5f1c0b9?page=128"> at day 30 and 100 were 7.5% (n=3) and 10% (n=4), </a> <a title="EBMT Supplement 2014 page 129" href="http://viewer.zmags.com/publication/d5f1c0b9?page=129"> Discussion: We selected the relatively homogeneou</a> <a title="EBMT Supplement 2014 page 130" href="http://viewer.zmags.com/publication/d5f1c0b9?page=130"> increased risk of cancer. Hematopoietic stem cell</a> <a title="EBMT Supplement 2014 page 131" href="http://viewer.zmags.com/publication/d5f1c0b9?page=131"> the favorable factor on overall survival (HR 1.99</a> <a title="EBMT Supplement 2014 page 132" href="http://viewer.zmags.com/publication/d5f1c0b9?page=132"> PH-P045 DEFINING PARTIAL REMISSION AFTER IMMUNOSU</a> <a title="EBMT Supplement 2014 page 133" href="http://viewer.zmags.com/publication/d5f1c0b9?page=133"> had received fludarabine during conditioning ther</a> <a title="EBMT Supplement 2014 page 134" href="http://viewer.zmags.com/publication/d5f1c0b9?page=134"> PH-P049 HEMATOPOIETIC STEM CELL TRANSPLANTATION F</a> <a title="EBMT Supplement 2014 page 135" href="http://viewer.zmags.com/publication/d5f1c0b9?page=135"> Cell Therapy PH-P051 VIRUS SPECIFIC CYTOTOXIC </a> <a title="EBMT Supplement 2014 page 136" href="http://viewer.zmags.com/publication/d5f1c0b9?page=136"> frequent complications after allogeneic stem cell</a> <a title="EBMT Supplement 2014 page 137" href="http://viewer.zmags.com/publication/d5f1c0b9?page=137"> are regarded as partial responders (PR) and patie</a> <a title="EBMT Supplement 2014 page 138" href="http://viewer.zmags.com/publication/d5f1c0b9?page=138"> showing that only recipient-alloreactive T-cells </a> <a title="EBMT Supplement 2014 page 139" href="http://viewer.zmags.com/publication/d5f1c0b9?page=139"> PH-P060 GENERATION OF TUMOR-SPECIFIC CYTOTOXIC T-</a> <a title="EBMT Supplement 2014 page 140" href="http://viewer.zmags.com/publication/d5f1c0b9?page=140"> is commonly achieved after one or more overnight </a> <a title="EBMT Supplement 2014 page 141" href="http://viewer.zmags.com/publication/d5f1c0b9?page=141"> [PH-P064] Discussion: Our ap</a> <a title="EBMT Supplement 2014 page 142" href="http://viewer.zmags.com/publication/d5f1c0b9?page=142"> Samples that were positive in FCXM were analyzed </a> <a title="EBMT Supplement 2014 page 143" href="http://viewer.zmags.com/publication/d5f1c0b9?page=143"> PH-P069 HUMAN MESENCHYMAL STROMAL CELLS, IN THE P</a> <a title="EBMT Supplement 2014 page 144" href="http://viewer.zmags.com/publication/d5f1c0b9?page=144"> containing rhIL-2. The expanded populations were </a> <a title="EBMT Supplement 2014 page 145" href="http://viewer.zmags.com/publication/d5f1c0b9?page=145"> (AML). The preparative regimen consisted of inter</a> <a title="EBMT Supplement 2014 page 146" href="http://viewer.zmags.com/publication/d5f1c0b9?page=146"> PH-P076 INFLUENCE OF KIR GENOTYPE ON SURVIVAL IN </a> <a title="EBMT Supplement 2014 page 147" href="http://viewer.zmags.com/publication/d5f1c0b9?page=147"> expression of which is epigenetically regulated. </a> <a title="EBMT Supplement 2014 page 148" href="http://viewer.zmags.com/publication/d5f1c0b9?page=148"> a median number of 10x106 cells. To evaluate the </a> <a title="EBMT Supplement 2014 page 149" href="http://viewer.zmags.com/publication/d5f1c0b9?page=149"> PH-P082 CHARACTERIZATION OF THE IN VITRO IMMUNOMO</a> <a title="EBMT Supplement 2014 page 150" href="http://viewer.zmags.com/publication/d5f1c0b9?page=150"> and IL10(M2c) and evaluated phenotypically and fu</a> <a title="EBMT Supplement 2014 page 151" href="http://viewer.zmags.com/publication/d5f1c0b9?page=151"> indication for RIT in CLL pts. Typically chronic </a> <a title="EBMT Supplement 2014 page 152" href="http://viewer.zmags.com/publication/d5f1c0b9?page=152"> PH-P089 STEM CELL TRANSPLANTATION FOR CML IN CHIL</a> <a title="EBMT Supplement 2014 page 153" href="http://viewer.zmags.com/publication/d5f1c0b9?page=153"> for high-risk CLL between June 2005 and April 201</a> <a title="EBMT Supplement 2014 page 154" href="http://viewer.zmags.com/publication/d5f1c0b9?page=154"> risk pts. Post-transplant SE resulted in improved</a> <a title="EBMT Supplement 2014 page 155" href="http://viewer.zmags.com/publication/d5f1c0b9?page=155"> Results: Results. Engraftment was achieved in 90 </a> <a title="EBMT Supplement 2014 page 156" href="http://viewer.zmags.com/publication/d5f1c0b9?page=156"> to the patients and in terms of therapeutic decis</a> <a title="EBMT Supplement 2014 page 157" href="http://viewer.zmags.com/publication/d5f1c0b9?page=157"> regimen. Bone marrow fibrosis was graded accordin</a> <a title="EBMT Supplement 2014 page 158" href="http://viewer.zmags.com/publication/d5f1c0b9?page=158"> PH-P102 IMPROVED RELAPSE-FREE SURVIVAL AFTER T-CE</a> <a title="EBMT Supplement 2014 page 159" href="http://viewer.zmags.com/publication/d5f1c0b9?page=159"> PH-P104 CORD BLOOD T LYMPHOCYTES EXPANSION FOR TH</a> <a title="EBMT Supplement 2014 page 160" href="http://viewer.zmags.com/publication/d5f1c0b9?page=160"> Profiling, detection/selection of T-cell-recep</a> <a title="EBMT Supplement 2014 page 161" href="http://viewer.zmags.com/publication/d5f1c0b9?page=161"> PH-P108 EXPRESSION OF SURFACE-ASSOCIATED METALLO-</a> <a title="EBMT Supplement 2014 page 162" href="http://viewer.zmags.com/publication/d5f1c0b9?page=162"> PH-P110 FEASIBILITY OF ALPHA BETA T- CELL DEPLETE</a> <a title="EBMT Supplement 2014 page 163" href="http://viewer.zmags.com/publication/d5f1c0b9?page=163"> minimal residual disease (MRD, n = 1), and for a </a> <a title="EBMT Supplement 2014 page 164" href="http://viewer.zmags.com/publication/d5f1c0b9?page=164"> PH-P115 NEGATIVE SELECTION BY APOPTOSIS ENRICHES </a> <a title="EBMT Supplement 2014 page 165" href="http://viewer.zmags.com/publication/d5f1c0b9?page=165"> [PH-P117] revDRI subgroup </a> <a title="EBMT Supplement 2014 page 166" href="http://viewer.zmags.com/publication/d5f1c0b9?page=166"> Patient D Weight kg Cond</a> <a title="EBMT Supplement 2014 page 167" href="http://viewer.zmags.com/publication/d5f1c0b9?page=167"> Materials (or patients) and Methods: The current </a> <a title="EBMT Supplement 2014 page 168" href="http://viewer.zmags.com/publication/d5f1c0b9?page=168"> PH-P122 PRIOR MD-ARAC CHEMOTHERAPY AFFECTING PERI</a> <a title="EBMT Supplement 2014 page 169" href="http://viewer.zmags.com/publication/d5f1c0b9?page=169"> Technologies, Vancouver, Canada). Subsequently, t</a> <a title="EBMT Supplement 2014 page 170" href="http://viewer.zmags.com/publication/d5f1c0b9?page=170"> administered as a single dose (n=19), or in fract</a> <a title="EBMT Supplement 2014 page 171" href="http://viewer.zmags.com/publication/d5f1c0b9?page=171"> PH-P127 IMPLEMENTATION OF NONCRYOPRESERVED GRAFTS</a> <a title="EBMT Supplement 2014 page 172" href="http://viewer.zmags.com/publication/d5f1c0b9?page=172"> [PH-P128] </a> <a title="EBMT Supplement 2014 page 173" href="http://viewer.zmags.com/publication/d5f1c0b9?page=173"> PH-P130 SINGLE CENTRE EXPERIENCE OF SECOND ALLOGE</a> <a title="EBMT Supplement 2014 page 174" href="http://viewer.zmags.com/publication/d5f1c0b9?page=174"> with decreased viability of cells. Trypan blue as</a> <a title="EBMT Supplement 2014 page 175" href="http://viewer.zmags.com/publication/d5f1c0b9?page=175"> corresponding to a CD34 CE2 of 62% (21-139%). Six</a> <a title="EBMT Supplement 2014 page 176" href="http://viewer.zmags.com/publication/d5f1c0b9?page=176"> Lymphoma PH-P137 PHASE 2 TRIAL OF HIGH-DOSE GE</a> <a title="EBMT Supplement 2014 page 177" href="http://viewer.zmags.com/publication/d5f1c0b9?page=177"> and logistics, and a committed donor. This proced</a> <a title="EBMT Supplement 2014 page 178" href="http://viewer.zmags.com/publication/d5f1c0b9?page=178"> mantle cell lymphoma, four patients with an anapl</a> <a title="EBMT Supplement 2014 page 179" href="http://viewer.zmags.com/publication/d5f1c0b9?page=179"> least one progression after inclusion. Twelve pat</a> <a title="EBMT Supplement 2014 page 180" href="http://viewer.zmags.com/publication/d5f1c0b9?page=180"> produce disease control. Many patients with HDC A</a> <a title="EBMT Supplement 2014 page 181" href="http://viewer.zmags.com/publication/d5f1c0b9?page=181"> PH-P147 BENDABEAM PLUS AUTOLOGOUS STEM CELL TRANS</a> <a title="EBMT Supplement 2014 page 182" href="http://viewer.zmags.com/publication/d5f1c0b9?page=182"> calculated from the time of allo-HCT. Kaplan-Meie</a> <a title="EBMT Supplement 2014 page 183" href="http://viewer.zmags.com/publication/d5f1c0b9?page=183"> conditioning regimen, unrelated donor, aGVHD, wer</a> <a title="EBMT Supplement 2014 page 184" href="http://viewer.zmags.com/publication/d5f1c0b9?page=184"> Materials (or patients) and Methods: We identifie</a> <a title="EBMT Supplement 2014 page 185" href="http://viewer.zmags.com/publication/d5f1c0b9?page=185"> 3-year overall survival of 74% (82% in ALCL ALK+ </a> <a title="EBMT Supplement 2014 page 186" href="http://viewer.zmags.com/publication/d5f1c0b9?page=186"> PH-P158 TREATMENT RESPONSE OF EATL PATIENTS IN AM</a> <a title="EBMT Supplement 2014 page 187" href="http://viewer.zmags.com/publication/d5f1c0b9?page=187"> chemotherapy, 67/112 (60%) were not eligible for </a> <a title="EBMT Supplement 2014 page 188" href="http://viewer.zmags.com/publication/d5f1c0b9?page=188"> PH-P162 LOWER RELAPSE AND BETTER PROGRESSION FREE</a> <a title="EBMT Supplement 2014 page 189" href="http://viewer.zmags.com/publication/d5f1c0b9?page=189"> chemotherapy programs (R-HDS) and autologous stem</a> <a title="EBMT Supplement 2014 page 190" href="http://viewer.zmags.com/publication/d5f1c0b9?page=190"> better OS than those who proceeded to alloSCT or </a> <a title="EBMT Supplement 2014 page 191" href="http://viewer.zmags.com/publication/d5f1c0b9?page=191"> studying maintenance approaches for eligible MCL </a> <a title="EBMT Supplement 2014 page 192" href="http://viewer.zmags.com/publication/d5f1c0b9?page=192"> PH-P171 EFFICACY OF AZACITIDINE TO RESTORE FULL D</a> <a title="EBMT Supplement 2014 page 193" href="http://viewer.zmags.com/publication/d5f1c0b9?page=193"> PH-P173 PREDICTIVE ROLE OF MINIMAL RESIDUAL DISEA</a> <a title="EBMT Supplement 2014 page 194" href="http://viewer.zmags.com/publication/d5f1c0b9?page=194"> Materials (or patients) and Methods: one hundred </a> <a title="EBMT Supplement 2014 page 195" href="http://viewer.zmags.com/publication/d5f1c0b9?page=195"> patients have been alive for over 60 months since</a> <a title="EBMT Supplement 2014 page 196" href="http://viewer.zmags.com/publication/d5f1c0b9?page=196"> rescue those high risk MDS-AML patients rendered </a> <a title="EBMT Supplement 2014 page 197" href="http://viewer.zmags.com/publication/d5f1c0b9?page=197"> therapy as growth factors, hypomethylating agents</a> <a title="EBMT Supplement 2014 page 198" href="http://viewer.zmags.com/publication/d5f1c0b9?page=198"> [PH-P183] PH-P184 </a> <a title="EBMT Supplement 2014 page 199" href="http://viewer.zmags.com/publication/d5f1c0b9?page=199"> PH-P185 THIOTEPA-BASED CONDITIONING FOLLOWED BY A</a> <a title="EBMT Supplement 2014 page 200" href="http://viewer.zmags.com/publication/d5f1c0b9?page=200"> Materials (or patients) and Methods: Allo-HSCT we</a> <a title="EBMT Supplement 2014 page 201" href="http://viewer.zmags.com/publication/d5f1c0b9?page=201"> osteogenic and adipogenic differentiation potenti</a> <a title="EBMT Supplement 2014 page 202" href="http://viewer.zmags.com/publication/d5f1c0b9?page=202"> differentiation. Only the set of down-regulated g</a> <a title="EBMT Supplement 2014 page 203" href="http://viewer.zmags.com/publication/d5f1c0b9?page=203"> approximately 2 weeks after inoculation, colonies</a> <a title="EBMT Supplement 2014 page 204" href="http://viewer.zmags.com/publication/d5f1c0b9?page=204"> follows: HLA identical sibling, n=4; unrelated do</a> <a title="EBMT Supplement 2014 page 205" href="http://viewer.zmags.com/publication/d5f1c0b9?page=205"> Results: After RIC2, 201 patients (88,5%) engraft</a> <a title="EBMT Supplement 2014 page 206" href="http://viewer.zmags.com/publication/d5f1c0b9?page=206"> [PH-P198] </a> <a title="EBMT Supplement 2014 page 207" href="http://viewer.zmags.com/publication/d5f1c0b9?page=207"> PH-P200 ALLOGENEIC STEM CELL TRANSPLANTATION FOR </a> <a title="EBMT Supplement 2014 page 208" href="http://viewer.zmags.com/publication/d5f1c0b9?page=208"> PH-P202 ALLOGENEIC STEM CELL TRANSPLANTATION IN P</a> <a title="EBMT Supplement 2014 page 209" href="http://viewer.zmags.com/publication/d5f1c0b9?page=209"> Results: At a median follow up of 57 months (3-15</a> <a title="EBMT Supplement 2014 page 210" href="http://viewer.zmags.com/publication/d5f1c0b9?page=210"> Results: On univariate analysis outcomes at three</a> <a title="EBMT Supplement 2014 page 211" href="http://viewer.zmags.com/publication/d5f1c0b9?page=211"> [PH-P207] probabilities of</a> <a title="EBMT Supplement 2014 page 212" href="http://viewer.zmags.com/publication/d5f1c0b9?page=212"> Materials (or patients) and Methods: A retr</a> <a title="EBMT Supplement 2014 page 213" href="http://viewer.zmags.com/publication/d5f1c0b9?page=213"> increased number of small collagen IV positive ve</a> <a title="EBMT Supplement 2014 page 214" href="http://viewer.zmags.com/publication/d5f1c0b9?page=214"> 11 metastatic primary cell lines: 319M, 531MII, 5</a> <a title="EBMT Supplement 2014 page 215" href="http://viewer.zmags.com/publication/d5f1c0b9?page=215"> The expression of the most important ligands was </a> <a title="EBMT Supplement 2014 page 216" href="http://viewer.zmags.com/publication/d5f1c0b9?page=216"> PH-P219 BUSULPHAN-MELPHALAN VERSUS CARBOPLATIN- E</a> <a title="EBMT Supplement 2014 page 217" href="http://viewer.zmags.com/publication/d5f1c0b9?page=217"> of EBV-specific autologous polyclonal CTL therapy</a> <a title="EBMT Supplement 2014 page 218" href="http://viewer.zmags.com/publication/d5f1c0b9?page=218"> GVHD was 43% for the younger group and 17% for th</a> <a title="EBMT Supplement 2014 page 219" href="http://viewer.zmags.com/publication/d5f1c0b9?page=219"> reduced-intensity conditioning, and the use of an</a> <a title="EBMT Supplement 2014 page 220" href="http://viewer.zmags.com/publication/d5f1c0b9?page=220"> PH-P228 IS THE BONE MARROW ASSESSMENT AN EVALUAT</a> <a title="EBMT Supplement 2014 page 221" href="http://viewer.zmags.com/publication/d5f1c0b9?page=221"> 296/336 (88%) pts were evaluable for donor identi</a> <a title="EBMT Supplement 2014 page 222" href="http://viewer.zmags.com/publication/d5f1c0b9?page=222"> quality requirements. All second HSC donations an</a> <a title="EBMT Supplement 2014 page 223" href="http://viewer.zmags.com/publication/d5f1c0b9?page=223"> 2. High product volume using the Optia is sig</a> <a title="EBMT Supplement 2014 page 224" href="http://viewer.zmags.com/publication/d5f1c0b9?page=224"> lymphoma. Peripheral blood stem cells have become</a> <a title="EBMT Supplement 2014 page 225" href="http://viewer.zmags.com/publication/d5f1c0b9?page=225"> doses given at the beginning of the conditioning </a> <a title="EBMT Supplement 2014 page 226" href="http://viewer.zmags.com/publication/d5f1c0b9?page=226"> were studied by flow cytometry. CD3/CD8/CD45/CD4 </a> <a title="EBMT Supplement 2014 page 227" href="http://viewer.zmags.com/publication/d5f1c0b9?page=227"> of micro-costing group interviews with local hosp</a> <a title="EBMT Supplement 2014 page 228" href="http://viewer.zmags.com/publication/d5f1c0b9?page=228"> suggest SCT can be performed safely on patients (</a> <a title="EBMT Supplement 2014 page 229" href="http://viewer.zmags.com/publication/d5f1c0b9?page=229"> proportion of patients (n= 21 or 8%) received ple</a> <a title="EBMT Supplement 2014 page 230" href="http://viewer.zmags.com/publication/d5f1c0b9?page=230"> PH-P250 FILGRASTIM (BIOSIMILAR) IN ALTERNATE DAYS</a> <a title="EBMT Supplement 2014 page 231" href="http://viewer.zmags.com/publication/d5f1c0b9?page=231"> PH-P252 SELECTIVE PHOTODEPLETION OF RECIPIENT-ALL</a> <a title="EBMT Supplement 2014 page 232" href="http://viewer.zmags.com/publication/d5f1c0b9?page=232"> the Optia Spectra produces grafts with less WBC b</a> <a title="EBMT Supplement 2014 page 233" href="http://viewer.zmags.com/publication/d5f1c0b9?page=233"> apy before HSC collection. Mobilization with G-CS</a> <a title="EBMT Supplement 2014 page 234" href="http://viewer.zmags.com/publication/d5f1c0b9?page=234"> patients were males (54%). The median age was 49 </a> <a title="EBMT Supplement 2014 page 235" href="http://viewer.zmags.com/publication/d5f1c0b9?page=235"> combination in the two groups. The GVHD prophylax</a> <a title="EBMT Supplement 2014 page 236" href="http://viewer.zmags.com/publication/d5f1c0b9?page=236"> [PH-P261] sHLA-G levels wer</a> <a title="EBMT Supplement 2014 page 237" href="http://viewer.zmags.com/publication/d5f1c0b9?page=237"> PH-P263 DETERMINANTS OF ENGRAFTMENT AND SINGLE-UN</a> <a title="EBMT Supplement 2014 page 238" href="http://viewer.zmags.com/publication/d5f1c0b9?page=238"> Plerixafor use were (i) a CD34 cell count ≤ 20/µL</a> <a title="EBMT Supplement 2014 page 239" href="http://viewer.zmags.com/publication/d5f1c0b9?page=239"> (78.3%) underwent transplantation in CR1 (34 PBSC</a> <a title="EBMT Supplement 2014 page 240" href="http://viewer.zmags.com/publication/d5f1c0b9?page=240"> shown that a higher number of CD34 cells infused </a> <a title="EBMT Supplement 2014 page 241" href="http://viewer.zmags.com/publication/d5f1c0b9?page=241"> [PH-P272] out within trials of</a> <a title="EBMT Supplement 2014 page 242" href="http://viewer.zmags.com/publication/d5f1c0b9?page=242"> longer time to engraftment and with a higher risk</a> <a title="EBMT Supplement 2014 page 243" href="http://viewer.zmags.com/publication/d5f1c0b9?page=243"> second allo-transplantations, whereas in only 16%</a> <a title="EBMT Supplement 2014 page 244" href="http://viewer.zmags.com/publication/d5f1c0b9?page=244"> from 23 centres. 28 pts in national prospective c</a> <a title="EBMT Supplement 2014 page 245" href="http://viewer.zmags.com/publication/d5f1c0b9?page=245"> tained a med of 2.3x106 CD3+/kg (1.2-5) and of 0.</a> <a title="EBMT Supplement 2014 page 246" href="http://viewer.zmags.com/publication/d5f1c0b9?page=246"> may obtain engraftment with smaller cell dose tha</a> <a title="EBMT Supplement 2014 page 247" href="http://viewer.zmags.com/publication/d5f1c0b9?page=247"> PH-P285 IMPACT OF THE HEMATOPOIETIC STEM CELL SOU</a> <a title="EBMT Supplement 2014 page 248" href="http://viewer.zmags.com/publication/d5f1c0b9?page=248"> Optia since the beginning of its utilisation in o</a> <a title="EBMT Supplement 2014 page 249" href="http://viewer.zmags.com/publication/d5f1c0b9?page=249"> age (r=0,11) and single gestation pregnancy (r=0,</a> <a title="EBMT Supplement 2014 page 250" href="http://viewer.zmags.com/publication/d5f1c0b9?page=250"> Despite multiple HLA disparities, development of </a> <a title="EBMT Supplement 2014 page 251" href="http://viewer.zmags.com/publication/d5f1c0b9?page=251"> Results: The ROC curve results indicate that the </a> <a title="EBMT Supplement 2014 page 252" href="http://viewer.zmags.com/publication/d5f1c0b9?page=252"> are important effector cells, which can be expand</a> <a title="EBMT Supplement 2014 page 253" href="http://viewer.zmags.com/publication/d5f1c0b9?page=253"> Discussion: Hence, these data reveal that the kin</a> <a title="EBMT Supplement 2014 page 254" href="http://viewer.zmags.com/publication/d5f1c0b9?page=254"> Preemptive DLI infusion for mixed chimerism post </a> <a title="EBMT Supplement 2014 page 255" href="http://viewer.zmags.com/publication/d5f1c0b9?page=255"> 30cells/uL – P=0.003). CI of grade II-IV acute GV</a> <a title="EBMT Supplement 2014 page 256" href="http://viewer.zmags.com/publication/d5f1c0b9?page=256"> PH-P306 QUALITY OF LIFE EVALUATIONS IN MULTIPLE S</a> <a title="EBMT Supplement 2014 page 257" href="http://viewer.zmags.com/publication/d5f1c0b9?page=257"> PH-P308 AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSP</a> <a title="EBMT Supplement 2014 page 258" href="http://viewer.zmags.com/publication/d5f1c0b9?page=258"> of the patients experienced neither acute nor chr</a> <a title="EBMT Supplement 2014 page 259" href="http://viewer.zmags.com/publication/d5f1c0b9?page=259"> +47 and +27 days respectively, successfully treat</a> <a title="EBMT Supplement 2014 page 260" href="http://viewer.zmags.com/publication/d5f1c0b9?page=260"> disease (CD). We analyze the long term effects of</a> <a title="EBMT Supplement 2014 page 261" href="http://viewer.zmags.com/publication/d5f1c0b9?page=261"> the SF-36 the only subscales that were different </a> <a title="EBMT Supplement 2014 page 262" href="http://viewer.zmags.com/publication/d5f1c0b9?page=262"> inclusion of high-dose CY in transplant regimens </a> <a title="EBMT Supplement 2014 page 263" href="http://viewer.zmags.com/publication/d5f1c0b9?page=263"> in weight loss and failure. All required data wer</a> <a title="EBMT Supplement 2014 page 264" href="http://viewer.zmags.com/publication/d5f1c0b9?page=264"> [PH-P322] Age Active 1 CR MUD </a> <a title="EBMT Supplement 2014 page 265" href="http://viewer.zmags.com/publication/d5f1c0b9?page=265"> respectively. They were treated with intrapul</a> <a title="EBMT Supplement 2014 page 266" href="http://viewer.zmags.com/publication/d5f1c0b9?page=266"> patients receiving iron chelators had significant</a> <a title="EBMT Supplement 2014 page 267" href="http://viewer.zmags.com/publication/d5f1c0b9?page=267"> PH-P329 RISK FACTORS FOR POSTERIOR REVERSIBLE ENC</a> <a title="EBMT Supplement 2014 page 268" href="http://viewer.zmags.com/publication/d5f1c0b9?page=268"> outcomes including non-relapse mortality (NRM) af</a> <a title="EBMT Supplement 2014 page 269" href="http://viewer.zmags.com/publication/d5f1c0b9?page=269"> for incomplete records. Patients were grouped as</a> <a title="EBMT Supplement 2014 page 270" href="http://viewer.zmags.com/publication/d5f1c0b9?page=270"> lung injury and 2 patients with IPS. We identifie</a> <a title="EBMT Supplement 2014 page 271" href="http://viewer.zmags.com/publication/d5f1c0b9?page=271"> PH-P337 DISCONTINUING IMMUNOSUPPRESSIVE THERAPY F</a> <a title="EBMT Supplement 2014 page 272" href="http://viewer.zmags.com/publication/d5f1c0b9?page=272"> We present our preliminary experience w</a> <a title="EBMT Supplement 2014 page 273" href="http://viewer.zmags.com/publication/d5f1c0b9?page=273"> psychological issues in ASCT patients, especially</a> <a title="EBMT Supplement 2014 page 274" href="http://viewer.zmags.com/publication/d5f1c0b9?page=274"> Discussion: In conclusion, second allo-HSCT shoul</a> <a title="EBMT Supplement 2014 page 275" href="http://viewer.zmags.com/publication/d5f1c0b9?page=275"> Discussion: We believe this dramatic reduction of</a> <a title="EBMT Supplement 2014 page 276" href="http://viewer.zmags.com/publication/d5f1c0b9?page=276"> PH-P349 REHABILITATION NEEDS IN HEMATOLOGY AND BO</a> <a title="EBMT Supplement 2014 page 277" href="http://viewer.zmags.com/publication/d5f1c0b9?page=277"> PH-P351 ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSP</a> <a title="EBMT Supplement 2014 page 278" href="http://viewer.zmags.com/publication/d5f1c0b9?page=278"> impact of EBMT score on survival underlines the i</a> <a title="EBMT Supplement 2014 page 279" href="http://viewer.zmags.com/publication/d5f1c0b9?page=279"> ferritin level >1000 ng/mL was found in 30 (59%) </a> <a title="EBMT Supplement 2014 page 280" href="http://viewer.zmags.com/publication/d5f1c0b9?page=280"> characteristics of hepatic VOD in children after </a> <a title="EBMT Supplement 2014 page 281" href="http://viewer.zmags.com/publication/d5f1c0b9?page=281"> Table 1. Patient characteristics NP Group </a> <a title="EBMT Supplement 2014 page 282" href="http://viewer.zmags.com/publication/d5f1c0b9?page=282"> [PH-P360] Control No</a> <a title="EBMT Supplement 2014 page 283" href="http://viewer.zmags.com/publication/d5f1c0b9?page=283"> [PH-P362] between the t</a> <a title="EBMT Supplement 2014 page 284" href="http://viewer.zmags.com/publication/d5f1c0b9?page=284"> PH-P364 EXTRAMEDULLARY RELAPSE OF ACUTE LEUKEMIA </a> <a title="EBMT Supplement 2014 page 285" href="http://viewer.zmags.com/publication/d5f1c0b9?page=285"> Furthermore, multivariate analysis showed respons</a> <a title="EBMT Supplement 2014 page 286" href="http://viewer.zmags.com/publication/d5f1c0b9?page=286"> [PH-P368] number Disease </a> <a title="EBMT Supplement 2014 page 287" href="http://viewer.zmags.com/publication/d5f1c0b9?page=287"> PH-P370 IMPACT OF GLUTATHİONE S-TRANSFERASE AND C</a> <a title="EBMT Supplement 2014 page 288" href="http://viewer.zmags.com/publication/d5f1c0b9?page=288"> Discussion: The prevalence of cardiovascular risk</a> <a title="EBMT Supplement 2014 page 289" href="http://viewer.zmags.com/publication/d5f1c0b9?page=289"> None Declared, Y. Nakashima: None Declared, T. Ta</a> <a title="EBMT Supplement 2014 page 290" href="http://viewer.zmags.com/publication/d5f1c0b9?page=290"> PH-P376 ADOPTIVE TRANSFER OF ALLOGENEIC REGULATOR</a> <a title="EBMT Supplement 2014 page 291" href="http://viewer.zmags.com/publication/d5f1c0b9?page=291"> PH-P378 RISK FACTORS FOR STEROID-REFRACTORY ACUTE</a> <a title="EBMT Supplement 2014 page 292" href="http://viewer.zmags.com/publication/d5f1c0b9?page=292"> (ATG) reduces the risk of GVHD, the impact of FM </a> <a title="EBMT Supplement 2014 page 293" href="http://viewer.zmags.com/publication/d5f1c0b9?page=293"> PH-P382 HUMAN CHORIONIC GONADOTROPIN HORMONE INDU</a> <a title="EBMT Supplement 2014 page 294" href="http://viewer.zmags.com/publication/d5f1c0b9?page=294"> PH-P384 UNDER-EXPOSURE TO MYCOPHENOLATE ACID (MPA</a> <a title="EBMT Supplement 2014 page 295" href="http://viewer.zmags.com/publication/d5f1c0b9?page=295"> conditioning. Underlying diseases were chronic my</a> <a title="EBMT Supplement 2014 page 296" href="http://viewer.zmags.com/publication/d5f1c0b9?page=296"> [PH-P388] </a> <a title="EBMT Supplement 2014 page 297" href="http://viewer.zmags.com/publication/d5f1c0b9?page=297"> PH-P390 CIRCULATING ENDOTHELIAL CELLS COUNT CHANG</a> <a title="EBMT Supplement 2014 page 298" href="http://viewer.zmags.com/publication/d5f1c0b9?page=298"> recipients of a graft from a sex-matched unrelate</a> <a title="EBMT Supplement 2014 page 299" href="http://viewer.zmags.com/publication/d5f1c0b9?page=299"> [PH-P394] Age Diagnosis Transplant</a> <a title="EBMT Supplement 2014 page 300" href="http://viewer.zmags.com/publication/d5f1c0b9?page=300"> reduced the incidence of GVHD in a small pilot tr</a> <a title="EBMT Supplement 2014 page 301" href="http://viewer.zmags.com/publication/d5f1c0b9?page=301"> (stage 2 or higher) or not (272.9 ± 101 vs 126.7 </a> <a title="EBMT Supplement 2014 page 302" href="http://viewer.zmags.com/publication/d5f1c0b9?page=302"> PH-P400 OUTCOME OF CHILDREN DEVELOPING GRADE III-</a> <a title="EBMT Supplement 2014 page 303" href="http://viewer.zmags.com/publication/d5f1c0b9?page=303"> PIT, Med Tech Solutions Gmbh, Fürt, Germany), add</a> <a title="EBMT Supplement 2014 page 304" href="http://viewer.zmags.com/publication/d5f1c0b9?page=304"> Results: As a whole, 36/72 (50.7%) of the patient</a> <a title="EBMT Supplement 2014 page 305" href="http://viewer.zmags.com/publication/d5f1c0b9?page=305"> Materials (or patients) and Methods: The study co</a> <a title="EBMT Supplement 2014 page 306" href="http://viewer.zmags.com/publication/d5f1c0b9?page=306"> of Genes and Genomes; www.genome.jp/kegg) wa</a> <a title="EBMT Supplement 2014 page 307" href="http://viewer.zmags.com/publication/d5f1c0b9?page=307"> Severe hypoalbuminemia was not associated with a </a> <a title="EBMT Supplement 2014 page 308" href="http://viewer.zmags.com/publication/d5f1c0b9?page=308"> [PH-P411] </a> <a title="EBMT Supplement 2014 page 309" href="http://viewer.zmags.com/publication/d5f1c0b9?page=309"> PH-P413 ORAL METRONIDAZOLE IN COMBINATION WITH QU</a> <a title="EBMT Supplement 2014 page 310" href="http://viewer.zmags.com/publication/d5f1c0b9?page=310"> summarizes patients' and GvHD characteristics. Al</a> <a title="EBMT Supplement 2014 page 311" href="http://viewer.zmags.com/publication/d5f1c0b9?page=311"> [PH-P417] PH-P418 IMPAIRE</a> <a title="EBMT Supplement 2014 page 312" href="http://viewer.zmags.com/publication/d5f1c0b9?page=312"> Dermatology, Rehabilitation, Neurology, and other</a> <a title="EBMT Supplement 2014 page 313" href="http://viewer.zmags.com/publication/d5f1c0b9?page=313"> PH-P421 LARGE SCALE CLINICAL CHARACTERIZATION OF </a> <a title="EBMT Supplement 2014 page 314" href="http://viewer.zmags.com/publication/d5f1c0b9?page=314"> Results: all patients showed an increase in TGGT </a> <a title="EBMT Supplement 2014 page 315" href="http://viewer.zmags.com/publication/d5f1c0b9?page=315"> unmanipulated hematopoietc stem cell transplantat</a> <a title="EBMT Supplement 2014 page 316" href="http://viewer.zmags.com/publication/d5f1c0b9?page=316"> tacrolimus included hypomagnesemia (100 %), renal</a> <a title="EBMT Supplement 2014 page 317" href="http://viewer.zmags.com/publication/d5f1c0b9?page=317"> and transplantation. The release of soluble HLA-G</a> <a title="EBMT Supplement 2014 page 318" href="http://viewer.zmags.com/publication/d5f1c0b9?page=318"> AML (71), ALL (15), MPN (6), lymphoma (11), MDS (</a> <a title="EBMT Supplement 2014 page 319" href="http://viewer.zmags.com/publication/d5f1c0b9?page=319"> refractory acute GVHD despite association with co</a> <a title="EBMT Supplement 2014 page 320" href="http://viewer.zmags.com/publication/d5f1c0b9?page=320"> Graft-versus-host Disease–Preclinical and Animal </a> <a title="EBMT Supplement 2014 page 321" href="http://viewer.zmags.com/publication/d5f1c0b9?page=321"> [PH-P438] </a> <a title="EBMT Supplement 2014 page 322" href="http://viewer.zmags.com/publication/d5f1c0b9?page=322"> between 50% and 70%. In in vitro cultures stimula</a> <a title="EBMT Supplement 2014 page 323" href="http://viewer.zmags.com/publication/d5f1c0b9?page=323"> MNCs). Moreover, exposure of PB and CB MNCs with </a> <a title="EBMT Supplement 2014 page 324" href="http://viewer.zmags.com/publication/d5f1c0b9?page=324"> identified. Expression of skin homing receptor, c</a> <a title="EBMT Supplement 2014 page 325" href="http://viewer.zmags.com/publication/d5f1c0b9?page=325"> temperature compound and snap frozen. In subseque</a> <a title="EBMT Supplement 2014 page 326" href="http://viewer.zmags.com/publication/d5f1c0b9?page=326"> nevertheless no improvement was observed. After t</a> <a title="EBMT Supplement 2014 page 327" href="http://viewer.zmags.com/publication/d5f1c0b9?page=327"> PH-P451 THIRTY YEARS' EXPERIENCE OF ALLOGENEIC HE</a> <a title="EBMT Supplement 2014 page 328" href="http://viewer.zmags.com/publication/d5f1c0b9?page=328"> PH-P453 HEMATOPOIETIC STEM CELL TRANSPLANTATION F</a> <a title="EBMT Supplement 2014 page 329" href="http://viewer.zmags.com/publication/d5f1c0b9?page=329"> However, there is no published evidence on effica</a> <a title="EBMT Supplement 2014 page 330" href="http://viewer.zmags.com/publication/d5f1c0b9?page=330"> ates, migrates and replace the deficient en</a> <a title="EBMT Supplement 2014 page 331" href="http://viewer.zmags.com/publication/d5f1c0b9?page=331"> Chimerism for first HSCT patient was 95% at 2 yea</a> <a title="EBMT Supplement 2014 page 332" href="http://viewer.zmags.com/publication/d5f1c0b9?page=332"> (100%) were chimeric with 100 % myeloid in 7/7 (1</a> <a title="EBMT Supplement 2014 page 333" href="http://viewer.zmags.com/publication/d5f1c0b9?page=333"> HSCT patients was 29 yrs (range 2-61) and 26% had</a> <a title="EBMT Supplement 2014 page 334" href="http://viewer.zmags.com/publication/d5f1c0b9?page=334"> PH-P466 FRENCH REAL LIFE COHORT ON THE USE OF MIC</a> <a title="EBMT Supplement 2014 page 335" href="http://viewer.zmags.com/publication/d5f1c0b9?page=335"> HIV infection, hematological malignancies and tra</a> <a title="EBMT Supplement 2014 page 336" href="http://viewer.zmags.com/publication/d5f1c0b9?page=336"> (< 38.5 °C) and transient fever presenting early </a> <a title="EBMT Supplement 2014 page 337" href="http://viewer.zmags.com/publication/d5f1c0b9?page=337"> Discussion: HBV reactivation in highly immunosupp</a> <a title="EBMT Supplement 2014 page 338" href="http://viewer.zmags.com/publication/d5f1c0b9?page=338"> PH-P475 PROLONGED FLUCONAZOLE PROPHYLAXIS IS NOT </a> <a title="EBMT Supplement 2014 page 339" href="http://viewer.zmags.com/publication/d5f1c0b9?page=339"> characteristic memory B cell response is defined </a> <a title="EBMT Supplement 2014 page 340" href="http://viewer.zmags.com/publication/d5f1c0b9?page=340"> PH-P479 EBV- ASSOCIATED DISEASES POST ALLOGENEIC </a> <a title="EBMT Supplement 2014 page 341" href="http://viewer.zmags.com/publication/d5f1c0b9?page=341"> immunosoppression and acute GVHD. First line ther</a> <a title="EBMT Supplement 2014 page 342" href="http://viewer.zmags.com/publication/d5f1c0b9?page=342"> cell (HSCT) or organ transplantation (SOT). Early</a> <a title="EBMT Supplement 2014 page 343" href="http://viewer.zmags.com/publication/d5f1c0b9?page=343"> thereafter on all pts admitted to the division of</a> <a title="EBMT Supplement 2014 page 344" href="http://viewer.zmags.com/publication/d5f1c0b9?page=344"> SCT more than 2 months (P-value 0.035). The overa</a> <a title="EBMT Supplement 2014 page 345" href="http://viewer.zmags.com/publication/d5f1c0b9?page=345"> discussion. Here, we provide clinical data of EBV</a> <a title="EBMT Supplement 2014 page 346" href="http://viewer.zmags.com/publication/d5f1c0b9?page=346"> 14 colonized (40%) and 17 not colonized (22%, P=0</a> <a title="EBMT Supplement 2014 page 347" href="http://viewer.zmags.com/publication/d5f1c0b9?page=347"> PH-P495 HUMAN HERPESVIRUS 6 REACTIVATION ASSOCIAT</a> <a title="EBMT Supplement 2014 page 348" href="http://viewer.zmags.com/publication/d5f1c0b9?page=348"> PH-P496 GAMMA-HERPESVIRUS LOAD AS SURROGATE MARKE</a> <a title="EBMT Supplement 2014 page 349" href="http://viewer.zmags.com/publication/d5f1c0b9?page=349"> period. The median time between the last hematolo</a> <a title="EBMT Supplement 2014 page 350" href="http://viewer.zmags.com/publication/d5f1c0b9?page=350"> presentations compatible with viral illness or Gv</a> <a title="EBMT Supplement 2014 page 351" href="http://viewer.zmags.com/publication/d5f1c0b9?page=351"> Materials (or patients) and Methods: All patients</a> <a title="EBMT Supplement 2014 page 352" href="http://viewer.zmags.com/publication/d5f1c0b9?page=352"> differences in the functional signature of </a> <a title="EBMT Supplement 2014 page 353" href="http://viewer.zmags.com/publication/d5f1c0b9?page=353"> In our population other consistent risk factors (</a> <a title="EBMT Supplement 2014 page 354" href="http://viewer.zmags.com/publication/d5f1c0b9?page=354"> owing mainly to the relatively low frequency of H</a> <a title="EBMT Supplement 2014 page 355" href="http://viewer.zmags.com/publication/d5f1c0b9?page=355"> MDR isolates were: MDR Pseudomonas aureginosa, 28</a> <a title="EBMT Supplement 2014 page 356" href="http://viewer.zmags.com/publication/d5f1c0b9?page=356"> of renal failure on prognosis of multiple myeloma</a> <a title="EBMT Supplement 2014 page 357" href="http://viewer.zmags.com/publication/d5f1c0b9?page=357"> and 2011 at Nantes. The cohort included 23 males </a> <a title="EBMT Supplement 2014 page 358" href="http://viewer.zmags.com/publication/d5f1c0b9?page=358"> is needed to determine whether there is any signi</a> <a title="EBMT Supplement 2014 page 359" href="http://viewer.zmags.com/publication/d5f1c0b9?page=359"> [PH-P519] PH-P520 AUTOLOG</a> <a title="EBMT Supplement 2014 page 360" href="http://viewer.zmags.com/publication/d5f1c0b9?page=360"> PH-P521 AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSP</a> <a title="EBMT Supplement 2014 page 361" href="http://viewer.zmags.com/publication/d5f1c0b9?page=361"> Grade II-IV. 4 patients received DLI; 3 for disea</a> <a title="EBMT Supplement 2014 page 362" href="http://viewer.zmags.com/publication/d5f1c0b9?page=362"> the new studies have testified that the CD137 lig</a> <a title="EBMT Supplement 2014 page 363" href="http://viewer.zmags.com/publication/d5f1c0b9?page=363"> PH-P527 INFLUENCE OF ASCT ON DURATION OF RESPONSE</a> <a title="EBMT Supplement 2014 page 364" href="http://viewer.zmags.com/publication/d5f1c0b9?page=364"> and from those transplanted from 2004 till 2012. </a> <a title="EBMT Supplement 2014 page 365" href="http://viewer.zmags.com/publication/d5f1c0b9?page=365"> thiotepa/fludarabine plus other drugs such as bus</a> <a title="EBMT Supplement 2014 page 366" href="http://viewer.zmags.com/publication/d5f1c0b9?page=366"> complications do not differ from that of the non-</a> <a title="EBMT Supplement 2014 page 367" href="http://viewer.zmags.com/publication/d5f1c0b9?page=367"> outcome1. We have now updated our data with a lar</a> <a title="EBMT Supplement 2014 page 368" href="http://viewer.zmags.com/publication/d5f1c0b9?page=368"> [PH-P538] With median follo</a> <a title="EBMT Supplement 2014 page 369" href="http://viewer.zmags.com/publication/d5f1c0b9?page=369"> PH-P540 UK EXPERIENCE OF UNRELATED CORD BLOOD TRA</a> <a title="EBMT Supplement 2014 page 370" href="http://viewer.zmags.com/publication/d5f1c0b9?page=370"> PH-P542 OUTCOMES AFTER A SEQUENTIAL CLOFARABINE A</a> <a title="EBMT Supplement 2014 page 371" href="http://viewer.zmags.com/publication/d5f1c0b9?page=371"> for paid consultancy services, K.-W. Sykora: None</a> <a title="EBMT Supplement 2014 page 372" href="http://viewer.zmags.com/publication/d5f1c0b9?page=372"> CNS event (all but one were grade 1 or 2), most c</a> <a title="EBMT Supplement 2014 page 373" href="http://viewer.zmags.com/publication/d5f1c0b9?page=373"> PH-P548 VIRAL INFECTIONS IN CHILDREN AND ADOLESCE</a> <a title="EBMT Supplement 2014 page 374" href="http://viewer.zmags.com/publication/d5f1c0b9?page=374"> presented with no evidence of infection within 24</a> <a title="EBMT Supplement 2014 page 375" href="http://viewer.zmags.com/publication/d5f1c0b9?page=375"> Discussion: In this study a bio-analytical method</a> <a title="EBMT Supplement 2014 page 376" href="http://viewer.zmags.com/publication/d5f1c0b9?page=376"> and protein S deficiency who had a severe haemorr</a> <a title="EBMT Supplement 2014 page 377" href="http://viewer.zmags.com/publication/d5f1c0b9?page=377"> PH-P557 MAJOR ABO INCOMPATIBLE BONE MARROW TRANSP</a> <a title="EBMT Supplement 2014 page 378" href="http://viewer.zmags.com/publication/d5f1c0b9?page=378"> PH-P559 HAEMATOPOIETIC STEM CELL TRANSPLANTATION </a> <a title="EBMT Supplement 2014 page 379" href="http://viewer.zmags.com/publication/d5f1c0b9?page=379"> [PH-P560] PH-P5</a> <a title="EBMT Supplement 2014 page 380" href="http://viewer.zmags.com/publication/d5f1c0b9?page=380"> chemo-conditioning in children with ALL, the EBMT</a> <a title="EBMT Supplement 2014 page 381" href="http://viewer.zmags.com/publication/d5f1c0b9?page=381"> Median follow-up 226 days (range 18-895). The est</a> <a title="EBMT Supplement 2014 page 382" href="http://viewer.zmags.com/publication/d5f1c0b9?page=382"> recent promising strategy, due the maintenance of</a> <a title="EBMT Supplement 2014 page 383" href="http://viewer.zmags.com/publication/d5f1c0b9?page=383"> Median hepcidin and ferritin levels did not diffe</a> <a title="EBMT Supplement 2014 page 384" href="http://viewer.zmags.com/publication/d5f1c0b9?page=384"> The AUC for the first dose was compared with that</a> <a title="EBMT Supplement 2014 page 385" href="http://viewer.zmags.com/publication/d5f1c0b9?page=385"> PH-P574 REDUCED INTENSITY CONDITIONING HAPLOIDENT</a> <a title="EBMT Supplement 2014 page 386" href="http://viewer.zmags.com/publication/d5f1c0b9?page=386"> Materials (or patients) and Methods: From Oct-200</a> <a title="EBMT Supplement 2014 page 387" href="http://viewer.zmags.com/publication/d5f1c0b9?page=387"> PH-P578 ANESTHESIA FOR BRONHOSCOPY IN PEDIATRIC P</a> <a title="EBMT Supplement 2014 page 388" href="http://viewer.zmags.com/publication/d5f1c0b9?page=388"> [PH-P580] Materia</a> <a title="EBMT Supplement 2014 page 389" href="http://viewer.zmags.com/publication/d5f1c0b9?page=389"> sibling (P=0.0029) compared to ATG-10 group. Pri</a> <a title="EBMT Supplement 2014 page 390" href="http://viewer.zmags.com/publication/d5f1c0b9?page=390"> PH-P583 A TOTAL LYMPHOID IRRADIATION (TLI) BASED </a> <a title="EBMT Supplement 2014 page 391" href="http://viewer.zmags.com/publication/d5f1c0b9?page=391"> dermatitis (1), VOD (1), cyclosporine-induced neu</a> <a title="EBMT Supplement 2014 page 392" href="http://viewer.zmags.com/publication/d5f1c0b9?page=392"> cells (n=8) or TCR αβ+ lymphocytes (n=8) was used</a> <a title="EBMT Supplement 2014 page 393" href="http://viewer.zmags.com/publication/d5f1c0b9?page=393"> B lymphocytes, which is the most commonly accepte</a> <a title="EBMT Supplement 2014 page 394" href="http://viewer.zmags.com/publication/d5f1c0b9?page=394"> PH-P591 A SINGLE CENTER EXPERIENCE WITH ALLOGENEI</a> <a title="EBMT Supplement 2014 page 395" href="http://viewer.zmags.com/publication/d5f1c0b9?page=395"> Materials (or patients) and Methods: We performed</a> <a title="EBMT Supplement 2014 page 396" href="http://viewer.zmags.com/publication/d5f1c0b9?page=396"> ABSTRACTS OF THE NURSES GROUP ORAL SESSIONS </a> <a title="EBMT Supplement 2014 page 397" href="http://viewer.zmags.com/publication/d5f1c0b9?page=397"> Palliative care: Learning Program in Palliative c</a> <a title="EBMT Supplement 2014 page 398" href="http://viewer.zmags.com/publication/d5f1c0b9?page=398"> Oral Session 2 NO005 IMPLEMENTATION OF A PRE-HA</a> <a title="EBMT Supplement 2014 page 399" href="http://viewer.zmags.com/publication/d5f1c0b9?page=399"> clearly give more validity to the results if more</a> <a title="EBMT Supplement 2014 page 400" href="http://viewer.zmags.com/publication/d5f1c0b9?page=400"> of a severe diagnosis and to fulfill the patient'</a> <a title="EBMT Supplement 2014 page 401" href="http://viewer.zmags.com/publication/d5f1c0b9?page=401"> Table: Overview of moral deliberation meeting dis</a> <a title="EBMT Supplement 2014 page 402" href="http://viewer.zmags.com/publication/d5f1c0b9?page=402"> account. Data on this topic is still scarce and t</a> <a title="EBMT Supplement 2014 page 403" href="http://viewer.zmags.com/publication/d5f1c0b9?page=403"> patients without endangering patients or increasi</a> <a title="EBMT Supplement 2014 page 404" href="http://viewer.zmags.com/publication/d5f1c0b9?page=404"> NO019 MEDICATION NONADHERENCE TO TAKING IMMUNOSUP</a> <a title="EBMT Supplement 2014 page 405" href="http://viewer.zmags.com/publication/d5f1c0b9?page=405"> (PE), days on enteral nutrition (EN) both food ta</a> <a title="EBMT Supplement 2014 page 406" href="http://viewer.zmags.com/publication/d5f1c0b9?page=406"> 8 beds, 55 allo transplants/year, 19.8 nursing al</a> <a title="EBMT Supplement 2014 page 407" href="http://viewer.zmags.com/publication/d5f1c0b9?page=407"> NURSES POSTER SESSIONS Research Outcomes f</a> <a title="EBMT Supplement 2014 page 408" href="http://viewer.zmags.com/publication/d5f1c0b9?page=408"> expert nursing intervention and involvement from </a> <a title="EBMT Supplement 2014 page 409" href="http://viewer.zmags.com/publication/d5f1c0b9?page=409"> from the day after completion of the conditioning</a> <a title="EBMT Supplement 2014 page 410" href="http://viewer.zmags.com/publication/d5f1c0b9?page=410"> NP008 A RETROSPECTIVE STUDY OF NUTRITIONAL ASPECT</a> <a title="EBMT Supplement 2014 page 411" href="http://viewer.zmags.com/publication/d5f1c0b9?page=411"> NP011 PAIN BELIEFS AND AFFECTING FACTORS OF THE H</a> <a title="EBMT Supplement 2014 page 412" href="http://viewer.zmags.com/publication/d5f1c0b9?page=412"> fatality in neutropenic patients with vasopr</a> <a title="EBMT Supplement 2014 page 413" href="http://viewer.zmags.com/publication/d5f1c0b9?page=413"> NP015 DELIRIUM MANAGEMENT IN STEM CELL TRANSPLANT</a> <a title="EBMT Supplement 2014 page 414" href="http://viewer.zmags.com/publication/d5f1c0b9?page=414"> [NP016] </a> <a title="EBMT Supplement 2014 page 415" href="http://viewer.zmags.com/publication/d5f1c0b9?page=415"> and were provided with the FACT-EBMT Quality of L</a> <a title="EBMT Supplement 2014 page 416" href="http://viewer.zmags.com/publication/d5f1c0b9?page=416"> NP020 PROTECTION DURING HEMOPOIETIC STEM CELL TRA</a> <a title="EBMT Supplement 2014 page 417" href="http://viewer.zmags.com/publication/d5f1c0b9?page=417"> Method: We did Literature review to see if there </a> <a title="EBMT Supplement 2014 page 418" href="http://viewer.zmags.com/publication/d5f1c0b9?page=418"> Ambulatory NP025 AUTOLOGOUS PERIPHERAL BLOOD S</a> <a title="EBMT Supplement 2014 page 419" href="http://viewer.zmags.com/publication/d5f1c0b9?page=419"> [NP028] Results: Regime No of patients</a> <a title="EBMT Supplement 2014 page 420" href="http://viewer.zmags.com/publication/d5f1c0b9?page=420"> Method: We retrospectively evaluated a total numb</a> <a title="EBMT Supplement 2014 page 421" href="http://viewer.zmags.com/publication/d5f1c0b9?page=421"> Results: 1. Provide knowledge about the </a> <a title="EBMT Supplement 2014 page 422" href="http://viewer.zmags.com/publication/d5f1c0b9?page=422"> [NP034] versus COBE Spectra by </a> <a title="EBMT Supplement 2014 page 423" href="http://viewer.zmags.com/publication/d5f1c0b9?page=423"> Education for Patients NP037 SURVEY OF EDUCATI</a> <a title="EBMT Supplement 2014 page 424" href="http://viewer.zmags.com/publication/d5f1c0b9?page=424"> Results: We begin the application of multimedia c</a> <a title="EBMT Supplement 2014 page 425" href="http://viewer.zmags.com/publication/d5f1c0b9?page=425"> of HSCT, the nursing head of hematology unit, the</a> <a title="EBMT Supplement 2014 page 426" href="http://viewer.zmags.com/publication/d5f1c0b9?page=426"> Results: The baseline CLABSI rate in the 2011 (be</a> <a title="EBMT Supplement 2014 page 427" href="http://viewer.zmags.com/publication/d5f1c0b9?page=427"> Results: The methylated spirit as an antiseptic w</a> <a title="EBMT Supplement 2014 page 428" href="http://viewer.zmags.com/publication/d5f1c0b9?page=428"> compliance with the key international guidelines </a> <a title="EBMT Supplement 2014 page 429" href="http://viewer.zmags.com/publication/d5f1c0b9?page=429"> NP054 CONTINUOUS VENO-VENOUS HEMOFILTRATION IN BM</a> <a title="EBMT Supplement 2014 page 430" href="http://viewer.zmags.com/publication/d5f1c0b9?page=430"> growth, strengthening of professional sel</a> <a title="EBMT Supplement 2014 page 431" href="http://viewer.zmags.com/publication/d5f1c0b9?page=431"> of 30 minutes taught per week. When dedicating a </a> <a title="EBMT Supplement 2014 page 432" href="http://viewer.zmags.com/publication/d5f1c0b9?page=432"> Results: The trial included 49 MS and 23 </a> <a title="EBMT Supplement 2014 page 433" href="http://viewer.zmags.com/publication/d5f1c0b9?page=433"> problem list, will in the future be used to furth</a> <a title="EBMT Supplement 2014 page 434" href="http://viewer.zmags.com/publication/d5f1c0b9?page=434"> October/2013, in the BMT unit of a teaching hospi</a> <a title="EBMT Supplement 2014 page 435" href="http://viewer.zmags.com/publication/d5f1c0b9?page=435"> members felt about teambuilding, collaboratio</a> <a title="EBMT Supplement 2014 page 436" href="http://viewer.zmags.com/publication/d5f1c0b9?page=436"> NP073 TO EVALUATE THE NUMBER OF BACTERIAL AND FUN</a> <a title="EBMT Supplement 2014 page 437" href="http://viewer.zmags.com/publication/d5f1c0b9?page=437"> NP076 TOUCHING SCREEN. THE SCHOOL AT THE HOSPITAL</a> <a title="EBMT Supplement 2014 page 438" href="http://viewer.zmags.com/publication/d5f1c0b9?page=438"> NP079 SAFETY-MANAGEMENT FOR CRITICALLY ILL PAEDIA</a> <a title="EBMT Supplement 2014 page 439" href="http://viewer.zmags.com/publication/d5f1c0b9?page=439"> ABSTRACTS OF THE DATA MANAGEMENT GROUP Sta</a> <a title="EBMT Supplement 2014 page 440" href="http://viewer.zmags.com/publication/d5f1c0b9?page=440"> Dynamic prediction methods were applied to update</a> <a title="EBMT Supplement 2014 page 441" href="http://viewer.zmags.com/publication/d5f1c0b9?page=441"> DM-P003 COMPARING OUTCOME RESULTS BETWEEN HSCT CE</a> <a title="EBMT Supplement 2014 page 442" href="http://viewer.zmags.com/publication/d5f1c0b9?page=442"> DM-PO04 Year Popn/10 million SCT rate/10 </a> <a title="EBMT Supplement 2014 page 443" href="http://viewer.zmags.com/publication/d5f1c0b9?page=443"> ABSTRACTS OF THE QUALITY MANAGEMENT GROUP </a> <a title="EBMT Supplement 2014 page 444" href="http://viewer.zmags.com/publication/d5f1c0b9?page=444"> - Supervised training forms: These are sec</a> <a title="EBMT Supplement 2014 page 445" href="http://viewer.zmags.com/publication/d5f1c0b9?page=445"> form ISHAGE protocol is the most reliable me</a> <a title="EBMT Supplement 2014 page 446" href="http://viewer.zmags.com/publication/d5f1c0b9?page=446"> the SEC, the data for the Tissue Establishment co</a> <a title="EBMT Supplement 2014 page 447" href="http://viewer.zmags.com/publication/d5f1c0b9?page=447"> Materials (or patients) and Methods: the 99MS sys</a> <a title="EBMT Supplement 2014 page 448" href="http://viewer.zmags.com/publication/d5f1c0b9?page=448"> PUBLICATION ONLY Acute Leukaemia PH-AB00</a> <a title="EBMT Supplement 2014 page 449" href="http://viewer.zmags.com/publication/d5f1c0b9?page=449"> PH-AB003 POTENTIAL ROLE OF PPAR IN THE MONOCYTIC </a> <a title="EBMT Supplement 2014 page 450" href="http://viewer.zmags.com/publication/d5f1c0b9?page=450"> engraftment was 20d (range 15–23d). All patients </a> <a title="EBMT Supplement 2014 page 451" href="http://viewer.zmags.com/publication/d5f1c0b9?page=451"> Autoimmune Diseases PH-AB008 CLINICAL VALUE OF</a> <a title="EBMT Supplement 2014 page 452" href="http://viewer.zmags.com/publication/d5f1c0b9?page=452"> transplantation. Endoscopy, barium small bowel en</a> <a title="EBMT Supplement 2014 page 453" href="http://viewer.zmags.com/publication/d5f1c0b9?page=453"> Materials (or patients) and Methods: Eight CML pa</a> <a title="EBMT Supplement 2014 page 454" href="http://viewer.zmags.com/publication/d5f1c0b9?page=454"> with thalassemia. In our experience the treatment</a> <a title="EBMT Supplement 2014 page 455" href="http://viewer.zmags.com/publication/d5f1c0b9?page=455"> tion (allo-HSCT) has improved overall survival. S</a> <a title="EBMT Supplement 2014 page 456" href="http://viewer.zmags.com/publication/d5f1c0b9?page=456"> Discussion: This experience leads to the conclusi</a> <a title="EBMT Supplement 2014 page 457" href="http://viewer.zmags.com/publication/d5f1c0b9?page=457"> PH-AB022 HIGH DOSE CHEMOTHERAPY WITH NITROSOUREA,</a> <a title="EBMT Supplement 2014 page 458" href="http://viewer.zmags.com/publication/d5f1c0b9?page=458"> etoposide were alive and disease free at median f</a> <a title="EBMT Supplement 2014 page 459" href="http://viewer.zmags.com/publication/d5f1c0b9?page=459"> transplantation in relapse/refractory lymphoma pa</a> <a title="EBMT Supplement 2014 page 460" href="http://viewer.zmags.com/publication/d5f1c0b9?page=460"> The median follow up from the date of 1st ASCT wa</a> <a title="EBMT Supplement 2014 page 461" href="http://viewer.zmags.com/publication/d5f1c0b9?page=461"> transplantation (ASCT). However, the way of admin</a> <a title="EBMT Supplement 2014 page 462" href="http://viewer.zmags.com/publication/d5f1c0b9?page=462"> PH-AB034 MODERN TRENDS IN THE AUTOLOGOUS HEMATOPO</a> <a title="EBMT Supplement 2014 page 463" href="http://viewer.zmags.com/publication/d5f1c0b9?page=463"> PH-AB037 HIGH-DOSE CHEMOTHERAPY FOLLOWED BY AUTOL</a> <a title="EBMT Supplement 2014 page 464" href="http://viewer.zmags.com/publication/d5f1c0b9?page=464"> patients who received steroids have PFS at 5 year</a> <a title="EBMT Supplement 2014 page 465" href="http://viewer.zmags.com/publication/d5f1c0b9?page=465"> PH-AB042 IS THERE A ROLE FOR ALLOGENEIC HEMATOPOI</a> <a title="EBMT Supplement 2014 page 466" href="http://viewer.zmags.com/publication/d5f1c0b9?page=466"> Type of MM: 14 IgG (63.6%), 6 Bence-Jones (27.3%)</a> <a title="EBMT Supplement 2014 page 467" href="http://viewer.zmags.com/publication/d5f1c0b9?page=467"> Myelodysplasia PH-AB047 USAGE OF HYPOMETHYLATI</a> <a title="EBMT Supplement 2014 page 468" href="http://viewer.zmags.com/publication/d5f1c0b9?page=468"> Infectious Complications PH-AB049 THE PROFILE </a> <a title="EBMT Supplement 2014 page 469" href="http://viewer.zmags.com/publication/d5f1c0b9?page=469"> Materials (or patients) and Methods: The aim of p</a> <a title="EBMT Supplement 2014 page 470" href="http://viewer.zmags.com/publication/d5f1c0b9?page=470"> PH-AB053 ORAL VALGANCICLOVIR IS EFFECTIVE AS PRE-</a> <a title="EBMT Supplement 2014 page 471" href="http://viewer.zmags.com/publication/d5f1c0b9?page=471"> of HSV-1 in throat swab was positive, susceptibil</a> <a title="EBMT Supplement 2014 page 472" href="http://viewer.zmags.com/publication/d5f1c0b9?page=472"> PH-AB058 INCIDENCE OF CLOSTRIDIUM DIFFICILE INFEC</a> <a title="EBMT Supplement 2014 page 473" href="http://viewer.zmags.com/publication/d5f1c0b9?page=473"> PH-AB060 MACROPHOMINA PHASEOLINA AS AN EMERGING F</a> <a title="EBMT Supplement 2014 page 474" href="http://viewer.zmags.com/publication/d5f1c0b9?page=474"> PH-AB062 GRAM - NEGATIVE BACTERIAL ISOLATION IN S</a> <a title="EBMT Supplement 2014 page 475" href="http://viewer.zmags.com/publication/d5f1c0b9?page=475"> Discussion: Mortality related to CRE-KPC was abse</a> <a title="EBMT Supplement 2014 page 476" href="http://viewer.zmags.com/publication/d5f1c0b9?page=476"> was combined with gastroenteritis – in 3/9 (33.3%</a> <a title="EBMT Supplement 2014 page 477" href="http://viewer.zmags.com/publication/d5f1c0b9?page=477"> geneic HLA-identical sibling transplants, but req</a> <a title="EBMT Supplement 2014 page 478" href="http://viewer.zmags.com/publication/d5f1c0b9?page=478"> dominant diagnosis was myeloid malignancy: 61 (AM</a> <a title="EBMT Supplement 2014 page 479" href="http://viewer.zmags.com/publication/d5f1c0b9?page=479"> receiving prophylaxis with acyclovir. We found 84</a> <a title="EBMT Supplement 2014 page 480" href="http://viewer.zmags.com/publication/d5f1c0b9?page=480"> (26) and others (7). G-CSF was administered in 32</a> <a title="EBMT Supplement 2014 page 481" href="http://viewer.zmags.com/publication/d5f1c0b9?page=481"> related morbidity and mortality were recorded in </a> <a title="EBMT Supplement 2014 page 482" href="http://viewer.zmags.com/publication/d5f1c0b9?page=482"> neurological symptomatology is diverse: focal def</a> <a title="EBMT Supplement 2014 page 483" href="http://viewer.zmags.com/publication/d5f1c0b9?page=483"> tors and the inflammatory process remain unclear.</a> <a title="EBMT Supplement 2014 page 484" href="http://viewer.zmags.com/publication/d5f1c0b9?page=484"> Results: Patient 1 after SCT sple</a> <a title="EBMT Supplement 2014 page 485" href="http://viewer.zmags.com/publication/d5f1c0b9?page=485"> PH-AB088 REVERSIBLE NON-ISCHEMIC HEART FAILURE IN</a> <a title="EBMT Supplement 2014 page 486" href="http://viewer.zmags.com/publication/d5f1c0b9?page=486"> Discussion: Fertility counselling and preservatio</a> <a title="EBMT Supplement 2014 page 487" href="http://viewer.zmags.com/publication/d5f1c0b9?page=487"> Materials (or patients) and Methods: We analyzed </a> <a title="EBMT Supplement 2014 page 488" href="http://viewer.zmags.com/publication/d5f1c0b9?page=488"> 42.9% (9/21) to Asia, 50% (8/16) to Africa, and 7</a> <a title="EBMT Supplement 2014 page 489" href="http://viewer.zmags.com/publication/d5f1c0b9?page=489"> PH-AB097 POSTERIOR REVERSIBLE ENCEPHALOPATHY SYND</a> <a title="EBMT Supplement 2014 page 490" href="http://viewer.zmags.com/publication/d5f1c0b9?page=490"> Materials (or patients) and Methods: A five-year </a> <a title="EBMT Supplement 2014 page 491" href="http://viewer.zmags.com/publication/d5f1c0b9?page=491"> donor. The stem cell source was bone marrow in 25</a> <a title="EBMT Supplement 2014 page 492" href="http://viewer.zmags.com/publication/d5f1c0b9?page=492"> PH-AB104 GIANT CELL MYOCARDITIS AFTER ALLOGENEIC </a> <a title="EBMT Supplement 2014 page 493" href="http://viewer.zmags.com/publication/d5f1c0b9?page=493"> Discussion: ASCT still remains to be an effective</a> <a title="EBMT Supplement 2014 page 494" href="http://viewer.zmags.com/publication/d5f1c0b9?page=494"> Materials (or patients) and Methods: Aims: T</a> <a title="EBMT Supplement 2014 page 495" href="http://viewer.zmags.com/publication/d5f1c0b9?page=495"> PH-AB110 TREATMENT OF REFRACTORY HEMORRAGIC CYSTI</a> <a title="EBMT Supplement 2014 page 496" href="http://viewer.zmags.com/publication/d5f1c0b9?page=496"> Extensive chronic GVHD (skin and mucosal involvem</a> <a title="EBMT Supplement 2014 page 497" href="http://viewer.zmags.com/publication/d5f1c0b9?page=497"> two cycles of ESHAP regimen a short term partial </a> <a title="EBMT Supplement 2014 page 498" href="http://viewer.zmags.com/publication/d5f1c0b9?page=498"> ity reactions. A recent report revealed cyclospor</a> <a title="EBMT Supplement 2014 page 499" href="http://viewer.zmags.com/publication/d5f1c0b9?page=499"> PH-AB120 PLERIXAFOR USE FOR PERIPHERAL BLOOD STEM</a> <a title="EBMT Supplement 2014 page 500" href="http://viewer.zmags.com/publication/d5f1c0b9?page=500"> [PH-AB122] Patient (Δ) Age @ HSCT CR </a> <a title="EBMT Supplement 2014 page 501" href="http://viewer.zmags.com/publication/d5f1c0b9?page=501"> tical stem cell transplantation for severe aplast</a> <a title="EBMT Supplement 2014 page 502" href="http://viewer.zmags.com/publication/d5f1c0b9?page=502"> Discussion: Early diagnosis and treatment of chil</a> <a title="EBMT Supplement 2014 page 503" href="http://viewer.zmags.com/publication/d5f1c0b9?page=503"> hemorrhage have been reported and the nodules typ</a> <a title="EBMT Supplement 2014 page 504" href="http://viewer.zmags.com/publication/d5f1c0b9?page=504"> PH-AB131 HARVEST OF HEMATOPOIETIC PROGENITOR CELL</a> <a title="EBMT Supplement 2014 page 505" href="http://viewer.zmags.com/publication/d5f1c0b9?page=505"> three-year disease free survival was 71.7%±6.5. F</a> <a title="EBMT Supplement 2014 page 506" href="http://viewer.zmags.com/publication/d5f1c0b9?page=506"> PH-AB136 OUTCOME OF HEMATOPOIETIC STEM CELL TRANS</a> <a title="EBMT Supplement 2014 page 507" href="http://viewer.zmags.com/publication/d5f1c0b9?page=507"> ment. Enteral feeding and immunosuppressive thera</a> <a title="EBMT Supplement 2014 page 508" href="http://viewer.zmags.com/publication/d5f1c0b9?page=508"> men including busulfan and cyclophosphamide. Cycl</a> <a title="EBMT Supplement 2014 page 509" href="http://viewer.zmags.com/publication/d5f1c0b9?page=509"> elapsed from allo-HSCT. Finally, lung has to be c</a> <a title="EBMT Supplement 2014 page 510" href="http://viewer.zmags.com/publication/d5f1c0b9?page=510"> PH-AB145 DEFIBROTIDE FOR THE PREVENTION AND TREAT</a> <a title="EBMT Supplement 2014 page 511" href="http://viewer.zmags.com/publication/d5f1c0b9?page=511"> lon and CsA in post-HSCT NS. We used the same the</a> <a title="EBMT Supplement 2014 page 512" href="http://viewer.zmags.com/publication/d5f1c0b9?page=512"> survival was 86% (95% CI, 81–91%). Treatment rela</a> <a title="EBMT Supplement 2014 page 513" href="http://viewer.zmags.com/publication/d5f1c0b9?page=513"> Donors for DLI (Group III.) were able to collect </a> <a title="EBMT Supplement 2014 page 514" href="http://viewer.zmags.com/publication/d5f1c0b9?page=514"> determine whether the dose infused and PL has rel</a> <a title="EBMT Supplement 2014 page 515" href="http://viewer.zmags.com/publication/d5f1c0b9?page=515"> received in average 2 packed RBC and 3 platelet u</a> <a title="EBMT Supplement 2014 page 516" href="http://viewer.zmags.com/publication/d5f1c0b9?page=516"> PH-AB160 EFFECTIVE PLATELET DEPLETION PROCEDURE P</a> <a title="EBMT Supplement 2014 page 517" href="http://viewer.zmags.com/publication/d5f1c0b9?page=517"> many patients with relapsed Hodgkin and non-Hodgk</a> <a title="EBMT Supplement 2014 page 518" href="http://viewer.zmags.com/publication/d5f1c0b9?page=518"> of hematopoietic stem cells within bone marrow. T</a> <a title="EBMT Supplement 2014 page 519" href="http://viewer.zmags.com/publication/d5f1c0b9?page=519"> PH-AB168 COLLECTION EFFICIENCY OF HAEMATOPOIETIC </a> <a title="EBMT Supplement 2014 page 520" href="http://viewer.zmags.com/publication/d5f1c0b9?page=520"> PH-AB170 CO-EXPRESSION OF ACE AND PAI-1 GENES MUT</a> <a title="EBMT Supplement 2014 page 521" href="http://viewer.zmags.com/publication/d5f1c0b9?page=521"> an HLA-identical sibling (8–47.0%) and from unrel</a> <a title="EBMT Supplement 2014 page 522" href="http://viewer.zmags.com/publication/d5f1c0b9?page=522"> Discussion: Even though the viable CD34+ cell num</a> <a title="EBMT Supplement 2014 page 523" href="http://viewer.zmags.com/publication/d5f1c0b9?page=523"> · The intra-population HLA diversity of Arabs is </a> <a title="EBMT Supplement 2014 page 524" href="http://viewer.zmags.com/publication/d5f1c0b9?page=524"> nal T cells to paternal mHAg during the first pre</a> <a title="EBMT Supplement 2014 page 525" href="http://viewer.zmags.com/publication/d5f1c0b9?page=525"> Case #/Diagnosis / Donor age ( Dono</a> <a title="EBMT Supplement 2014 page 526" href="http://viewer.zmags.com/publication/d5f1c0b9?page=526"> mothers giving birth in the University Hospital o</a> <a title="EBMT Supplement 2014 page 527" href="http://viewer.zmags.com/publication/d5f1c0b9?page=527"> Discussion: Data analysis of 700 donor's collecti</a> <a title="EBMT Supplement 2014 page 528" href="http://viewer.zmags.com/publication/d5f1c0b9?page=528"> American TC. The Portuguese TC represented 53% fr</a> <a title="EBMT Supplement 2014 page 529" href="http://viewer.zmags.com/publication/d5f1c0b9?page=529"> PH-AB189 INCREASED T REGULATORY CELL, TH1 AND TH1</a> <a title="EBMT Supplement 2014 page 530" href="http://viewer.zmags.com/publication/d5f1c0b9?page=530"> PH-AB192 RESULTS OF MUD-HSCT IN CHILDREN WITH AML</a> <a title="EBMT Supplement 2014 page 531" href="http://viewer.zmags.com/publication/d5f1c0b9?page=531"> Materials (or patients) and Methods: A comparativ</a> <a title="EBMT Supplement 2014 page 532" href="http://viewer.zmags.com/publication/d5f1c0b9?page=532"> were included. 30 children were during preoperati</a> <a title="EBMT Supplement 2014 page 533" href="http://viewer.zmags.com/publication/d5f1c0b9?page=533"> number of collected and transplanted CD34+ cells </a> <a title="EBMT Supplement 2014 page 534" href="http://viewer.zmags.com/publication/d5f1c0b9?page=534"> Discussion: Both the COBE Spectra and Spectra Opt</a> <a title="EBMT Supplement 2014 page 535" href="http://viewer.zmags.com/publication/d5f1c0b9?page=535"> Discussion: Biosimilar G-CSF, such as Zarzio, may</a> <a title="EBMT Supplement 2014 page 536" href="http://viewer.zmags.com/publication/d5f1c0b9?page=536"> as the CY group (n=66), HD-CY, 1.5-4 g/m2 i.v., w</a> <a title="EBMT Supplement 2014 page 537" href="http://viewer.zmags.com/publication/d5f1c0b9?page=537"> PH-AB208 PLERIXAFOR: A MAGIC DRUG FOR URGENT PBSC</a> <a title="EBMT Supplement 2014 page 538" href="http://viewer.zmags.com/publication/d5f1c0b9?page=538"> >3×106 CD34+ cells per Kilogram achieve in first </a> <a title="EBMT Supplement 2014 page 539" href="http://viewer.zmags.com/publication/d5f1c0b9?page=539"> PH-AB213 THE NATIONAL SWEDISH CORD BLOOD BANK – A</a> <a title="EBMT Supplement 2014 page 540" href="http://viewer.zmags.com/publication/d5f1c0b9?page=540"> progenitor cell transplantation were studied. The</a> <a title="EBMT Supplement 2014 page 541" href="http://viewer.zmags.com/publication/d5f1c0b9?page=541"> get of ≥4×106/kg was reached in 70% of patients i</a> <a title="EBMT Supplement 2014 page 542" href="http://viewer.zmags.com/publication/d5f1c0b9?page=542"> PH-AB220 THE EFFECT OF CD34 POSİTİVE CELL SELECTİ</a> <a title="EBMT Supplement 2014 page 543" href="http://viewer.zmags.com/publication/d5f1c0b9?page=543"> PH-AB222 ENGRAFMENT AND OUTCOME AFTER AUTOLOGOUS </a> <a title="EBMT Supplement 2014 page 544" href="http://viewer.zmags.com/publication/d5f1c0b9?page=544"> 30% and aplastic bone marrow in 26%. Overall, 65%</a> <a title="EBMT Supplement 2014 page 545" href="http://viewer.zmags.com/publication/d5f1c0b9?page=545"> grade II-IV who later on died from TRM. Of these </a> <a title="EBMT Supplement 2014 page 546" href="http://viewer.zmags.com/publication/d5f1c0b9?page=546"> between MMUD and MUD groups on age, gender, phase</a> <a title="EBMT Supplement 2014 page 547" href="http://viewer.zmags.com/publication/d5f1c0b9?page=547"> Materials (or patients) and Methods: Peripheral b</a> <a title="EBMT Supplement 2014 page 548" href="http://viewer.zmags.com/publication/d5f1c0b9?page=548"> steroid/ ATG /ECP refractory skin GvHD following </a> <a title="EBMT Supplement 2014 page 549" href="http://viewer.zmags.com/publication/d5f1c0b9?page=549"> In only one patient biopsy did not allow to discr</a> <a title="EBMT Supplement 2014 page 550" href="http://viewer.zmags.com/publication/d5f1c0b9?page=550"> tomatic splenomegaly and constitutional symptoms </a> <a title="EBMT Supplement 2014 page 551" href="http://viewer.zmags.com/publication/d5f1c0b9?page=551"> PH-AB241 EXTRACORPOREAL PHOTOAFERESIS: AN EFFECTI</a> <a title="EBMT Supplement 2014 page 552" href="http://viewer.zmags.com/publication/d5f1c0b9?page=552"> These findings confirm the need for formal oral e</a> <a title="EBMT Supplement 2014 page 553" href="http://viewer.zmags.com/publication/d5f1c0b9?page=553"> PH-AB245 ILEOSTOMY AS A TREATMENT OPTION IN PATIE</a> <a title="EBMT Supplement 2014 page 554" href="http://viewer.zmags.com/publication/d5f1c0b9?page=554"> of ECP procedures were done in median 8 months (2</a> <a title="EBMT Supplement 2014 page 555" href="http://viewer.zmags.com/publication/d5f1c0b9?page=555"> (RV) and lung diffusion capacity for carbon dioxi</a> <a title="EBMT Supplement 2014 page 556" href="http://viewer.zmags.com/publication/d5f1c0b9?page=556"> conditioning regimen (myeloablative vs reduced in</a> <a title="EBMT Supplement 2014 page 557" href="http://viewer.zmags.com/publication/d5f1c0b9?page=557"> how acute or chronic GvHD may affect the T and NK</a> <a title="EBMT Supplement 2014 page 558" href="http://viewer.zmags.com/publication/d5f1c0b9?page=558"> fusion genes respectively, represent a very high </a> <a title="EBMT Supplement 2014 page 559" href="http://viewer.zmags.com/publication/d5f1c0b9?page=559"> ine 30 mg/m2/d days –13 to –9, Ara-C 1g/m2/d days</a> <a title="EBMT Supplement 2014 page 560" href="http://viewer.zmags.com/publication/d5f1c0b9?page=560"> PH-AB263 CLOFARABINE AS BRIDGE TO TRANSPLANTATION</a> <a title="EBMT Supplement 2014 page 561" href="http://viewer.zmags.com/publication/d5f1c0b9?page=561"> infusions (DLI) to successfully treat post-allo-H</a> <a title="EBMT Supplement 2014 page 562" href="http://viewer.zmags.com/publication/d5f1c0b9?page=562"> PH-AB267 RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC C</a> <a title="EBMT Supplement 2014 page 563" href="http://viewer.zmags.com/publication/d5f1c0b9?page=563"> and methotrexate or mycophenolate were used for G</a> <a title="EBMT Supplement 2014 page 564" href="http://viewer.zmags.com/publication/d5f1c0b9?page=564"> graft failure rates (P>0.05). In multivariate ana</a> <a title="EBMT Supplement 2014 page 565" href="http://viewer.zmags.com/publication/d5f1c0b9?page=565"> Functional profiling of CD4 and CD8 T lymphocytes</a> <a title="EBMT Supplement 2014 page 566" href="http://viewer.zmags.com/publication/d5f1c0b9?page=566"> PH-AB276 T-CELL RECEPTOR EXCISION CIRCLES LEVELS </a> <a title="EBMT Supplement 2014 page 567" href="http://viewer.zmags.com/publication/d5f1c0b9?page=567"> of T cell receptor excision circles (TRECs) and k</a> <a title="EBMT Supplement 2014 page 568" href="http://viewer.zmags.com/publication/d5f1c0b9?page=568"> etic stem cell transplantation (allo-HSCT) is ass</a> <a title="EBMT Supplement 2014 page 569" href="http://viewer.zmags.com/publication/d5f1c0b9?page=569"> of graft-vs-host disease. Transcriptional acti</a> <a title="EBMT Supplement 2014 page 570" href="http://viewer.zmags.com/publication/d5f1c0b9?page=570"> Aamdal, S. PH-P065 Aarup, T.L. NP014 Abbruzzese, </a> <a title="EBMT Supplement 2014 page 571" href="http://viewer.zmags.com/publication/d5f1c0b9?page=571"> Andre, M.C. PH-O118 Andreani, M. PH-O106, PH-P230</a> <a title="EBMT Supplement 2014 page 572" href="http://viewer.zmags.com/publication/d5f1c0b9?page=572"> Ball, L. WP-O031 Ball, L.M. PH-P541 Ball, L. NO01</a> <a title="EBMT Supplement 2014 page 573" href="http://viewer.zmags.com/publication/d5f1c0b9?page=573"> Bertasiute, A. PH-P402 Bertelli, L. PH-P331 Berth</a> <a title="EBMT Supplement 2014 page 574" href="http://viewer.zmags.com/publication/d5f1c0b9?page=574"> Boumendil, A. PH-O108, PH-O109, PH-O110, </a> <a title="EBMT Supplement 2014 page 575" href="http://viewer.zmags.com/publication/d5f1c0b9?page=575"> Carella, G. PH-P109, PH-P229 Cario, G. PH-AB131 C</a> <a title="EBMT Supplement 2014 page 576" href="http://viewer.zmags.com/publication/d5f1c0b9?page=576"> Chuansumrit, A. PH-O070 Chubukina, Z.V. PH-P014 C</a> <a title="EBMT Supplement 2014 page 577" href="http://viewer.zmags.com/publication/d5f1c0b9?page=577"> Dabaja, M. NP080 Dadwal, S.S. PH-P463, PH-P508 Da</a> <a title="EBMT Supplement 2014 page 578" href="http://viewer.zmags.com/publication/d5f1c0b9?page=578"> Di Piazza, F. PH-O153, PH-P018, PH-P230, NP0</a> <a title="EBMT Supplement 2014 page 579" href="http://viewer.zmags.com/publication/d5f1c0b9?page=579"> Elhasid, R. PH-P348, NP036, PH-AB136 Elhassan, T.</a> <a title="EBMT Supplement 2014 page 580" href="http://viewer.zmags.com/publication/d5f1c0b9?page=580"> FlØisand, Y. NP013 Flomenberg, N. PH-P260 Flommer</a> <a title="EBMT Supplement 2014 page 581" href="http://viewer.zmags.com/publication/d5f1c0b9?page=581"> Geromin, A. PH-P075, PH-P271, PH-AB173, PH-A</a> <a title="EBMT Supplement 2014 page 582" href="http://viewer.zmags.com/publication/d5f1c0b9?page=582"> Greczkowska, T. PH-AB196 Gregoire, L. PH-P068 Gré</a> <a title="EBMT Supplement 2014 page 583" href="http://viewer.zmags.com/publication/d5f1c0b9?page=583"> Hauri-Hohl, M. PH-O037 Hausmann, A. PH-P106, </a> <a title="EBMT Supplement 2014 page 584" href="http://viewer.zmags.com/publication/d5f1c0b9?page=584"> Ileri, T. PH-P453 Ilhan, O. PH-AB247 Illiaquer, M</a> <a title="EBMT Supplement 2014 page 585" href="http://viewer.zmags.com/publication/d5f1c0b9?page=585"> Karadurmus, N. PH-AB018, PH-AB090, PH-AB091 </a> <a title="EBMT Supplement 2014 page 586" href="http://viewer.zmags.com/publication/d5f1c0b9?page=586"> Kolstad, A. PH-P065 Kołtan, S. PH-AB192 Komarnick</a> <a title="EBMT Supplement 2014 page 587" href="http://viewer.zmags.com/publication/d5f1c0b9?page=587"> Ladetto, M. PH-P164 Lafarge, X. PH-P280 Lai, A. P</a> <a title="EBMT Supplement 2014 page 588" href="http://viewer.zmags.com/publication/d5f1c0b9?page=588"> Liwoch, R. PH-AB038 Lixia, L. PH-P023 Lizhen, L. </a> <a title="EBMT Supplement 2014 page 589" href="http://viewer.zmags.com/publication/d5f1c0b9?page=589"> Mancias-Guerra, C. PH-P555 Mancini, G. PH-O131 Ma</a> <a title="EBMT Supplement 2014 page 590" href="http://viewer.zmags.com/publication/d5f1c0b9?page=590"> Mear, J.-B. PH-AB153 Méchinaud, F. PH-P542 Medeot</a> <a title="EBMT Supplement 2014 page 591" href="http://viewer.zmags.com/publication/d5f1c0b9?page=591"> Moorjani, R. PH-P009, PH-P328 Moosavi, S.A. PH-P0</a> <a title="EBMT Supplement 2014 page 592" href="http://viewer.zmags.com/publication/d5f1c0b9?page=592"> Nielsen, C.H. PH-O044 Nielsen, J. PH-P325 Niemeye</a> <a title="EBMT Supplement 2014 page 593" href="http://viewer.zmags.com/publication/d5f1c0b9?page=593"> Özsan, G.H. PH-AB115 Ozturk, G. PH-P546, PH-AB053</a> <a title="EBMT Supplement 2014 page 594" href="http://viewer.zmags.com/publication/d5f1c0b9?page=594"> Pession, A. PH-O002, PH-O121, PH-P329, </a> <a title="EBMT Supplement 2014 page 595" href="http://viewer.zmags.com/publication/d5f1c0b9?page=595"> Radia, R. NP002 Radić, Krišto, D. PH-AB045 Radice</a> <a title="EBMT Supplement 2014 page 596" href="http://viewer.zmags.com/publication/d5f1c0b9?page=596"> Röper, B. PH-P222 Ropponen, A. PH-P241, PH-AB198 </a> <a title="EBMT Supplement 2014 page 597" href="http://viewer.zmags.com/publication/d5f1c0b9?page=597"> Saure, C. PH-P178 Sauter, C. PH-P149 Sauvezie, M.</a> <a title="EBMT Supplement 2014 page 598" href="http://viewer.zmags.com/publication/d5f1c0b9?page=598"> Shaw, A. PH-O004, PH-P046 Shaw, B.E. PH-O049, PH-</a> <a title="EBMT Supplement 2014 page 599" href="http://viewer.zmags.com/publication/d5f1c0b9?page=599"> Spínola, A.I. PH-P114, PH-AB186 Spirito, A. PH-P1</a> <a title="EBMT Supplement 2014 page 600" href="http://viewer.zmags.com/publication/d5f1c0b9?page=600"> Tegtmeier, B.R. PH-P463, PH-P508 Teichert von Lue</a> <a title="EBMT Supplement 2014 page 601" href="http://viewer.zmags.com/publication/d5f1c0b9?page=601"> Unal, E. PH-P154, PH-AB077, PH-AB098, PH-AB1</a> <a title="EBMT Supplement 2014 page 602" href="http://viewer.zmags.com/publication/d5f1c0b9?page=602"> Vokurka, S. PH-P085, PH-P086 Volchek, Y. PH-O046,</a> <a title="EBMT Supplement 2014 page 603" href="http://viewer.zmags.com/publication/d5f1c0b9?page=603"> PH-P262, PH-P313, PH-P415, PH-P435, </a>